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 7 
Summary 
 
 
PTPN22 encodes the lymphoid tyrosine phosphatase Lyp that can dephosphorylate 
Lck, ZAP-70 and Fyn to attenuate TCR signaling. A single-nucleotide polymorphism 
(C1858T) causes a substitution from arginine (R) to tryptophan (W) at 620 residue 
(R620W). Lyp-620W has been confirmed as a susceptible allele in multiple 
autoimmune diseases, including type 1 diabetes (T1D). Several independent studies 
proposed that the disease-associated allele is a gain-of-function variant. However, a 
recent report found that in human cells and a knockin mouse containing the R620W 
homolog that Ptpn22 protein degradation is accelerated, indicating Lyp-620W is a 
loss-of-function variant. Whether Lyp R620W is a gain- or loss-of-function variant 
remains controversial. To resolve this issue, we generated two lines (P2 and P4) of 
nonobese diabetic (NOD) mice in which Ptpn22 can be inducibly silenced by RNAi. 
We found long term silencing of Ptpn22 increased spleen cellularity and regulatory T 
(Treg) cell numbers, replicating the effect of gene deletion reported in the knockout 
(KO) B6 mice. Notably, Ptpn22 silencing also increased the reactivity and apoptotic 
behavior of B lymphocytes, which is consistent with the reduced reactivity and 
apoptosis of human B cells carrying the alleged gain-of-function PTPN22 allele. 
Furthermore, loss of Ptpn22 protected P2 KD mice from spontaneous and 
Cyclophosphamide (CY) induced diabetes. Our data support the notion that Lyp-
620W is a gain-of-function variant. Moreover, Lyp may be a valuable target for the 
treatment of autoimmune diseases.   
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Zusammenfassung 
 
PTPN22 kodiert die lymphoid tyrosine phosphatase Lyp, die Lck, ZAP-70 und Fyn 
dephosphorilieren kann, um T Zell Rezeptor Signale zu vermindern. Ein 
Polymorphismus (C1858T) verursacht einen Aminosäurenaustausch auf Position 620 
von Arginin zu Tryptophan (R620W). Lyp-620W erhöht das Risiko einer Vielfalt von 
Autoimmunerkrankungen, darunter auch Diabetes Typ 1 (T1D). Mehrere Studien 
haben belegt, dass dieses Krankheitsallel die Funktion von Lyp verstärkt. Eine neuere 
Studie hat andererseits gezeigt, dass die R620W Variante schneller degradiert wird, 
was bedeuten würde, dass das C1858T Allel einen Funktionsverlust verursachen 
könnte. Ob Lyp R620W die Funktion dieser Phosphatase erhöht oder mindert bleibt 
demnach bis jetzt ungewiss. Um diese Frage zu klären haben wir zwei transgene 
Mauslinien (P2 und P4) im diabetischen Hintergrund der NOD Maus generiert, in 
denen Ptpn22 auf induzierbare Weise durch RNAi gehemmt werden kann. Unsere 
Ergebnisse zeigen, dass die langfristige Hemmung von Ptpn22 zu einer Zunahme der 
Milzzellularität und der Anzahl regulatorischer T Zellen führt, was dem Phänotyp des 
Ptpn22 knockout im B6 Hintergrund entspricht. Bemerkenswert ist, dass die 
Hemmung von Ptpn22 auch zu einer Zunahme der Reaktivität und des apoptotischen 
Verhaltens von B Lymphozyten führt, also dem entgegengesetzten Phänotypen, der in 
menschlichen B Zellen beobachtet wurde, die das Krankheitsallel exprimierten. 
Zusätzlich konnte die Ptpn22 Inhibierung NOD Mäuse vor spontanem und 
Cyclophosphamid-induziertem Diabetes schützen. Unsere Daten unterstützen also die 
Hypothese, dass Lyp-620W eine stärkere Aktivität vorweist. Dies würde auch 
bedeuten, dass Ptpn22 möglicherweise zu therapeutischen Zwecken inhibiert werden 
könnte, um Autoimmunerkrankungen zu bekämpfen. 
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1.1 Type 1 diabetes 
 
Type 1 diabetes (T1D; also called insulin-dependent diabetes mellitus, IDDM) is an 
autoimmune disease, resulting from the infiltration of immune cells into the pancreas 
that cause the permanent destruction of insulin producing β cells. Multiple factors 
influence the susceptibility to T1D, including genetic and environmental factors. 
Although gender is a very important factor in many autoimmune diseases (women are 
generally more susceptible than men), males and females are almost equally prone to 
T1D (Beeson et al., 1994; Amur et al., 2011).  
 
Many studies have demonstrated that environmental factors, like virus infection, 
bacteria and diet, can accelerate or protect from T1D. In 1987, Foulis and colleagues 
reported that a large amount of IFN-α and HLA class Ι could be found in the islets of 
newly diabetic children, indicating that virus infection may be involved in T1D. 
Follow-up studies found that viruses, particularly enteroviruses and rotaviruses, may 
accelerate T1D by 1) molecular mimicry of autoantigens which are found in the islets 
(Kaufman et al., 1992); 2) directly infecting β cells to induce insulitis (Yoon et al., 
1978). In the case of bacteria, many studies have been done to clarify their role, 
especially that of commensal bacteria in T1D. Commensal bacteria are abundant in 
the gut and intestine. In 2002, Bach and colleagues demonstrated that commensal 
bacteria interfered with T1D in the NOD mouse (Bach et al., 2002). Li and colleagues 
further reported that commensal bacteria could protect the NOD mouse from T1D in a 
MyD88-independent manner (Li et al., 2008).  Another environmental factor, diet, 
also affects the susceptibility to T1D. Vitamin D was found to decrease the risk of 
T1D in the NOD mouse (Mathieu et al., 1994). Interestingly, some proteins in 
common food items can mimick autoantigens in the islets, which may accelerate the 
pathogenesis of T1D. For example, albumin in cow’s milk is a molecular mimick of 
ICA-1, which is a surface protein on β cells (Karjalainen et al., 1992). Moreover, 
there is elevated T cell reactivity to wheat gluten in the blood of T1D patients, 
although the cause of this is not clear (Klemetti et al., 1998).  
 
In the case of genetic factors, so far, multiple single-nucleotide polymorphisms 
(SNPs) have been identified in association with human T1D by genome-wide 
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association studies (GWAS) (Table1, modified from www.t1dbase.org).  
 
Table 1. T1D risk loci in humans (modified from www.t1dbase.org) 
 Chrom SNP Gene of Interest 
OR Minor Allele 
 (95% CI) Publication 
1 1p13.2 rs2476601 PTPN22 2.05 [1.90-2.20] Bottini et al., 2006 
2 1q31.2 rs2816316  0.89 [0.84-0.95] Smyth et al., 2008 
3 1q32.1 rs3024505 IL10, CD55 0.84 [0.77-0.91] Barrett et al., 2009 
4 2q11.2 rs1160542    
  rs9653442  1.11 [1.07-1.16]  
5 2q12.1 rs917997 IL18RAP 0.83 [0.72-0.96] Smyth  et al., 2008 
6 2q24.2 rs1990760 IFIH1 0.86 [0.82-0.90] Smyth  et al., 2006 
7 2q32.2 rs6752770 STAT4 1.11 [] 
  rs7574865  1.10 [1.04-1.15] 
Fung et al., 2009 
8 2q33.2 rs3087243 CTLA4 0.88 [0.83-0.93] 
Ueda et al., 2003 
Nisticò et al., 1998 
Smyth et al., 2008 
9 3p21.31 rs11711054   
  rs333  0.85 [0.80-0.92] 
Smyth et al., 2008 
10 4p15.2 rs10517086  1.09 [1.02-1.17] Barrett et al., 2009 
11 4q27 rs2069762 IL2 0.89 [0.85-0.93] 
  rs4505848   
Todd et al., 2007 
Cooper et al., 2008 
12 5p13.2 rs6897932 IL7R 0.89 [0.84-0.94] Todd et al., 2007 
13 
6p21.33, 
6p21.31 
rs9268645 HLA II  Nejentsev et al., 2007 
14 6q15 rs11755527 BACH2 1.13 [1.09-1.18] Cooper et al., 2008 
15 6q22.32 rs9388489  1.17 [1.10-1.24] Barrett et al., 2009 
16 6q23.3 rs6920220  1.09 [1.04-1.15] Fung et al., 2009 
17 6q25.3 rs1738074 TAGAP 0.92 [0.88-0.96] Smyth  et al., 2008 
18 7p15.2 rs7804356  0.88 [0.82-0.94] Barrett et al., 2009 
19 7p12.1 rs4948088  0.77 [0.67-0.90] Barrett et al., 2009 
20 9p24.2 rs7020673 GLIS3 0.88 [0.83-0.93] Barrett et al., 2009 
21 10p15.1 rs11594656 IL2RA 0.87 [0.82-0.92] 
  rs12722495  0.62 [0.57-0.68] 
Lowe et al., 2007 
22 10p15.1 rs11258747   Cooper et al., 2008 
  rs947474   
23 10q22.3 rs1250550   
  rs1250558   
 
24 10q23.31 rs10509540 RNLS 0.75 [0.70-0.80] Barrett et al., 2009 
25 11p15.5 rs689 INS 0.95 [0.89-1.03] 
  rs7111341   
Bell et al., 1984 
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26 12p13.31 rs4763879  1.09 [1.02-1.16] Barrett et al., 2009 
27 12q13.2 rs2292239 IKZF4 1.31 [1.22-1.34] 
Todd et al., 2007 
Hakonarson et al., 2008 
28 12q13.3 rs1678536  0.89 [0.82-0.97] 
  rs1678542  0.92 [0.88-0.96] 
Cooper et al., 2008 
Fung et al., 2009 
29 12q24.12 rs3184504 SH2B3 1.28 [1.22-1.35] 
Todd et al., 2007 
 
30 14q24.1 rs1465788  0.86 [0.80-0.91] Barrett et al., 2009 
31 14q32.2 rs4900384  1.09 [1.02-1.16] Barrett et al., 2009 
32 14q32.2 rs941576  0.90 [0.86-0.94] Wallace et al., 2010 
33 15q14 rs17574546   
  rs7171171   
Qu et al., 2009 
34 15q25.1 rs3825932  0.86 [0.82-0.90] Cooper et al., 2008 
35 16p13.13 rs12708716  0.81 [0.77-0.86] 
Todd et al., 2007 
Hakonarson et al., 2008 
36 16p11.2 rs4788084 IL27 0.86 [0.81-0.91] Barrett et al., 2009 
37 16q23.1 rs7202877  1.28 [1.17-1.41] Barrett et al., 2009 
38 17q12 rs2290400 
ORMDL3, 
GSDMB 
0.87 [0.82-0.93] Barrett et al., 2009 
39 17q21.2 rs7221109  0.95 [0.89-1.01] Barrett et al., 2009 
40 18p11.21 rs1893217 PTPN2  
  rs478582  0.83 [0.79-0.88] 
Todd et al., 2007 
41 18q22.2 rs763361 CD226 1.16 [1.10-1.22] Todd et al., 2007 
42 19p13.2 rs2304256  0.86 [0.82-0.90] Wallace et al., 2010 
43 19q13.32 rs425105  0.86 [0.79-0.93] Barrett et al., 2009 
44 20p13 rs2281808  0.90 [0.84-0.95] Barrett et al., 2009 
45 21q22.3 rs3788013 UBASH3A 1.13 [1.08-1.18] Concannon et al., 2008 
46 22q12.2 rs5753037  1.10 [1.04-1.17] Barrett et al., 2009 
47 22q12.3 rs3218253    
48 22q13.1 rs229541  1.12 [1.07-1.17] Cooper et al., 2008 
49 Xp22.2 rs5979785 TLR8 0.84 [0.73-0.96] Cooper et al., 2008 
50 Xq28 rs2664170  1.16 [1.07-1.24] Barrett et al., 2009 
 
Among so many identified genes, not every gene contributes to disease susceptibility 
equally.  A small number of them confer substantial effects. The risk factor HLA 
class II gene was discovered over 20 years ago. In familial T1D, it contributes to 40-
50% of the risk of developing disease. The insulin (INS) gene can also confer 
susceptibility or resistance to T1D. In humans, in the 5’ regulatory region of the 
insulin gene there is a unique variable number tandem repeat (VNTR), which comes 
from tandem repetition of a 14-15 base pair (bp) oligonucleotide sequence. Based on 
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the different sizes, VNTR is divided into three types: type 1 (26-63 repeats), type 2 
(about 80 repeats), and type 3 (141-209 repeats) (Bell et al., 1982; Rotwein P., 1986; 
Bennett et al., 1995). The type 1 allele increases disease risk 2-5 fold, whereas the 
type 3 allele is T1D protective. (Bell et al., 1984; Julier et al., 1991; Lucassen et al., 
1993; Owerbach et al., 1993; Julie et al., 1994; Undlien et al., 1995). Further study 
found that compared to type 1 VNTR, type 3 VNTR correlated with higher INS 
mRNA in thymus and lower mRNA in the pancreas, which benefited negative 
selection of T lymphocytes in the thymus and reduced self-antigen exposure in the 
pancreas. (Lucassen et al., 1995; Kennedy et al., 1995; Pugliese et al., 1997; Vafiadis 
et al., 1997; Vafiadis et al., 2001). 
 
CTLA-4 and PTPN22 are general risk factors in many human autoimmune diseases. 
PTPN22 will be discussed in a later section. CTLA-4 has been confirmed in 
association with many autoimmune diseases, including Multiple Sclerosis (Sawcer et 
al., 1996), T1D (Copeman et al., 1995), Graves' disease (Kouki et al., 2002), 
Hashimoto's thyroiditis (Nithiyananthan et al., 2002), Addison's disease and 
Rheumatoid Arthritis (Becker et al., 1998). CTLA-4 is a potent negative regulator of 
T cell activation. CTLA-4 knockout mice quickly died due to the massive 
lymphoproliferation and multiorgan destruction (Waterhouse et al., 1995; Tivol et al., 
1995). Specific loss of CTLA-4 in regulatory T cells (Treg cells) leads to the same 
symptom, but with delayed onset (Wing et al., 2008). CTLA-4 has been proposed to 
transmit negative signals by distinct mechanisms: 1) it could outcompete CD28 by 
virtue of a higher affinity for CD80/86, which provide costimulatory signal for T cell 
activation (Ostrov et al., 2000); 2) it may directly block immunoreceptor tyrosine-
based activation motif (ITAM) (Lee et al., 1998); 3) it could diminish CD80/86 
expression on antigen presenting cells (APCs) to ablate T cell costimulatory signal 
(Wing et al., 2008; Cedebom et al., 2000).  
 
In humans, CTLA-4 is located at chromosome 2q33. In the NOD mouse, Ctla-4 
resides in chromosome 1. In both human and mouse, CTLA-4 undergoes alternative 
splicing. Full length CTLA-4 (flCTLA-4) and soluble CTLA-4 (sCTLA-4) exist in 
both human and mouse.  FlCTLA-4 contains all the four domains (leader peptide, 
ligand binding domain, transmembrane domain and cytosolic tail), while sCTLA-4 
lacks the transmembrane domain. It is believed sCTLA4 is translated, secreted and 
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circulates in human serum (Magistrelli et al 1999, Oaks et al 2000). In humans, a 
SNPin the 3´ UTR (CT60, A/G) results in a reduced ratio of sCTLA-4/fl CTLA-4, 
which is associated with T1D susceptibility (Ueda, et al., 2003). Ligand independent 
CTLA-4 (liCTLA-4), which is unique in the mouse, lacks the ligand-binding domain. 
Vijayakrishnan and colleagues found that although liCTLA-4 lacks exon2 including 
the MYPPPY motif that is essential for CD80/86 binding, liCTLA-4 still could 
dephosphorylate the TcRζ chain and ZAP-70 in vitro (Vijayakrishnan et al., 2004).  
 
Besides the genes mentioned above, many other genes confer susceptibility to T1D. 
PTPN2 encodes a tyrosine phosphatase. A recent study found that PTPN2 is highly 
expressed in human islet cells and rat β cells. A decrease in PTPN2 could amplify 
IFN-γ induced STAT1 phosphorylation and β Cell apoptosis. PRKCQ, another 
candidate gene, acts in the downstream signaling cascade of the TCR, which plays an 
important role in T cell differentiation. In PRKCQ deficient mice, the number of Treg 
cells and CD4+ T cells are greatly decreased (Gupta et al., 2008). Yet another 
candidate, KIAA0350 (also known as Clec16a) belongs to calcium-dependent lectin 
(C-type lectin) superfamily, containing an ITAM in the cytosol. Ema, which is 
KIAA0350 homologue in drosophila, is involved in the endosomal maturation (Kim 
et al., 2010). The exact function of KIAA0350 in mouse and humans is still unknown. 
IFIH1 (also known as MDA5) selectively recognize the viral double strand RNA 
(dsRNA). Hence, IFIH1 plays important roles in antiviral responses. BACH2 encodes 
a leucine zipper transcription factor, which is very important for B cell class switch 
recombination (CSR) and somatic hypermutation (SHM). So BACH2 is a key 
regulator in antibody response and humoral immunity (Muto et al., 2004). 
 
So far dozens of SNPs have been implicated in T1D by GWAS. However, the 
functional consequences of most SNPs are largely unknown. It is also unknown how 
these SNPs accelerate or exacerbate T1D. To characterize the role of risk alleles in the 
pathogenesis of T1D, a mouse model for this disease, like the NOD mouse, provides a 
valuable resource. 
 
1.2 The non-obese diabetic (NOD) mouse model 
The NOD mouse strain was developed in Japan in 1970s by Makino and his 
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colleagues (Makino et al., 1980). This mouse strain harbors some inherent defects in 
central and peripheral tolerance, leading to immune cell infiltration into the pancreas, 
β cells destruction and spontaneous T1D (Anderson et al., 2005). In female NOD 
mice, the frequency of spontaneous diabetes is 60-80% at the age of 4-6 months, 
compared to 20-30% incidence in the male mice (Kikutani et al., 1992; Bach et al., 
1994). This incidence difference between male and female NOD mice may be related 
to sex hormones, illustrated by the decreased incidence in androgen treated female 
mice and increased incidence in castrated males (Fitzpatrick et al., 1991; Fox., 1992; 
Makino et al., 1981). However, this gender-related difference in T1D incidence is not 
significant in humans (Beeson et al., 1994; Amur et al., 2011). Besides T1D, in some 
conditions NOD mice are susceptible to other spontaneous or inducible autoimmune 
diseases, such as autoimmune sialitis (Hu et al., 1992), autoimmune thyroiditis (Many 
et al., 1996), experimental autoimmune encephalomyelitis (EAE) (Ichikawa et al., 
1999), autoimmune peripheral polyneuropathy (Salomon et al., 2001) and systemic 
lupus erythematosus–like disease (Silveira et al., 2001).  
 
The NOD mouse is a widely used mouse model for human T1D. NOD mice share 
many similarities with human T1D patients, including the presence of autoreactive T 
cells, autoreactive B cells, and similar risk loci in the genome. So far, more than 20 
potential Idd loci have been identified in the NOD mouse (Todd et al., 2001). As in 
humans, the disease susceptible MHC allele confers the largest risk. The NOD mouse 
has a unique MHC haplotype, termed H-2g7 (Wicker et al., 1995; Tisch et al., 1996). 
A nonaspartic acid replacement in H-2g7 alters T cell receptor (TCR) affinity and then 
changes the repertoire of MHC binding peptides (Acha-Orbea et al., 1987; Kanagawa 
et al., 1998). However, the H2g7alone is not sufficient for disease development. Other 
Idd loci, which contribute immune tolerance deficit, are required to induce T1D in the 
NOD mouse (Serreze et al., 2001). 
 
1.2.1 Defective tolerance in the NOD mouse 
Immune tolerance comprises two aspects: central tolerance and peripheral tolerance. 
In the NOD mouse, both central and peripheral tolerance is defective, leading to the 
disease development.  
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Fig 1.1: Relevant genes involved in the defective immune tolerance in T1D 
(Santamaria et al., 2010) 
 
1.2.1.1 Central tolerance in the NOD mouse 
Central tolerance happens during the process of T cell development in the thymus. 
During T cell maturation, positive and negative selections occur to optimize our 
immune system: to protect the body from harmful bacteria and viruses as well as to 
avoid self-tissue destruction. During positive selection, immature thymocytes reactive 
to self-antigen obtain a survival signal and proceed to negative selection. During 
negative selection, thymocytes with high affinity to self-antigen are deleted before 
they migrate into peripheral tissues. Negative selection, which eliminates most 
autoreactive T cells, is critical to maintain self tolerance. In the NOD mouse, negative 
selection is somehow defective, illustrated by the fact that some semi-mature 
thymocytes, which should be deleted by negative selection, escape from apoptosis 
(Kishimoto et al., 2001). Some of these escaped autoreactive T cells could destroy β 
cells by recognizing islet antigen, including insulin (Palmer et al., 1987), glutamic 
acid decarboxylase (GAD65) (Baekkeskov et al., 1989), and a tyrosine phosphatase 
like protein (IA-2) (Lan et al., 1996). 
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1.2.1.2 Peripheral tolerance in the NOD mouse 
The presence of autoreactive T cells is not exclusive to the NOD mouse. Negative 
selection is incomplete both in the NOD and in some disease resistant mice (Lohmann 
et al., 1996; Semana et al., 1999). T1D in the NOD mouse is also contributed to by 
defective peripheral tolerance dependent on anti-inflammatory cytokines, and several 
suppressive cell populations, including Treg cells, Tr1 (IL-10 producing cells), Th3 
(TGF-β producing T helper cells) and regulatory B cells (CD1dhiCD5+ B cells).  
 
Treg cells are pivotal in peripheral tolerance. Treg cells can be distinguished from 
other cells types by their unique transcription factor-FoxP3 and highly expressed cell 
surface markers, including CD25, CTLA-4, and GITR. Based on their origin, Treg 
cells are classified into two populations: natural Treg cells (nTreg cells; derived from 
thymus, FoxP3+Helios+) and induced Treg cells (iTreg; naïve T cells converted in the 
periphery, FoxP3+Helios-) (Thornton et al., 2010).  
 
So far, it is still controversial whether NOD mice harbor defective Treg cells. Two 
papers reported that in the NOD mouse the percentage of Treg cells was significantly 
decreased compared to that in disease resistant mouse strains (Wu et al., 2002; Alard 
et al., 2006). An opposite result was reported in 2007, claiming that NOD mice were 
superior in generating Treg cells, at least nTreg cells (Feuerer et al., 2007). D'Alise 
and colleagues reported that Treg cells from NOD and B6 mice were comparable in 
cell numbers and function. However, conventional T cells (Tconv, CD4+CD25-) from 
NOD mice are more proliferative than those from B6 mice (D'Alise et al., 2008). 
Nevertheless, there is no doubt that Treg cells are indispensable to control diabetes in 
the NOD mouse. On one hand, loss of Treg cells can accelerate or exacerbate T1D 
(Salomon et al., 2000; Mellanby et al., 2007). On the other hand, a boost in Treg cells 
by IL-2 treatment or by a genetic approach can protect and even reverse T1D (Peng et 
al., 2004; Grinberg-Bleyer et al., 2010). Adoptive transfer experiments also 
demonstrated that Treg cells are potent in controlling effector T cell induced 
autoimmunity in the NOD.scid mice (Asano et al., 1996; Stephens et al., 2000; 
Hutchings et al., 1990; Boitard et al., 1989; Lepault et al., 2000; Szanya et al., 2002). 
 
Since Treg cells are potent suppressors, an interesting question is a whether boost of 
Treg cells could control or cure autoimmune diseases. Since the frequency of Treg 
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cells in peripheral blood is quite low (1-5% in CD4+ cells), it is reasonable to isolate 
and then expand Treg cells ex vivo to obtain enough Treg cells. The Bluestone group 
at UCSF has conducted preclinical trials of transferring expanded Treg cells into 
diabetic patients. Treg cells are unable to proliferate unless their TCR and CD28 are 
continuously engaged by MHC/peptide and B7 molecules, respectively. Tang and 
colleagues succeeded in achieving a 200-fold Treg cell expansion within 2 weeks by 
utilizing high dose IL-2 and anti-CD3/CD28 coupled beads. The expanded Treg cells 
maintained their suppressive phenotype and function (Tang et al., 2004). The same 
group further expanded BDC 2.5 TCR transgenic Treg cells by coculture with 
autoantigen pulsed dentritic cells and IL-2. The expanded TCR specific Treg cells are 
more potent than polyclonal Treg cells to prevent/cure T1D in the NOD mouse 
(Tarbell et al., 2004). Wiegard and colleagues found that kupffer cell, which is a kind 
of macrophage in the liver, had the ability to expand Treg cells without IL-2. 
However, these expanded Treg cells were less suppressive compared to freshly 
isolated Treg cells (Wiegard et al., 2005). 
 
1.2.2 The role of different cell subsets in T1D 
It is an interesting question which cell population is vital in the pathogenesis of T1D 
in the NOD mouse. Immunodeficient mice, such as NOD.scid or NOD.Rag-/- mice 
which lack T and B cells, are protected from T1D (Katz et al., 1993; Prochazka et al., 
1992; Serreze et al., 1994; Soderstrom et al., 1996; Wicker et al., 1994). To further 
separate the role of T and B cells, adoptive transfer and cell depletion experiments 
have been employed. B cell depletion by rituximab, an anti-CD20 monoclonal 
antibody, preserves β cell function to some extent in newly diagnosed T1D patients 
(Pescovitz et al., 2009). In the mouse, loss of B cells protects NOD mice from T1D, 
and moreover, reverses the diseases in more than one third of diabetic mice (Serreze 
et al., 1996. Hu et al., 2007). This protection could be due to the disrupted antigen 
presentation to T cells, and increased number of Treg cells and regulatory B cells.  
Charlton and colleagues further utilized adoptive transfer experiments to define the 
time window during which B cells are required for disease pathogenesis. T cells alone 
from 5wks old mice are sufficient to induce diabetes in the NOD.scid mouse 
(Charlton et al., 2001). So it seems that B cells are critical in the early stage of 
diabetes (peri-insulitis and insulitis), but dispensable in the effector stage. T cells 
from young NOD mice are sufficient to kill beta cells independent of B cell 
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contribution.  
 
Further studies demonstrated that T cells are the primary cells in disease development. 
CD4+ T cells could transfer disease, and spontaneous diabetes was blocked in NOD 
mice by treatment with a monoclonal antibody against CD4 (Shizuru et al., 1988; 
Wang et al., 1991). Meanwhile, CD8+ T cells also promote disease development 
(Wang et al., 1996; Wong et al., 1996). CD8+ cells also infiltrate into the pancreas. 
These CD8+ cells express NKG2D, an activating receptor. Treatment with depleting 
monoclonal antibody against NKG2D in the prediabetic stage prevents CD8+ cell 
expansion and T1D development in mice (Ogasawara et al., 2004).  
 
1.2.3 The pathogenesis of T1D 
At the age of 3-4 weeks, mononuclear infiltration (peri-insulitis) occurs, without overt 
diabetes (Delovitch and Singh, 1997; Kanazawa et al., 1984). Disease progresses to 
severe insulitis by 10 weeks of age, and to overt symptoms at 4-6 months, resulting in 
high level of glucose in the blood and urine and loss of weight. As mentioned above, 
T cells are the key cell population causing NOD mice to proceed to the overt diabetic 
symptoms. However, T cells, including autoreactive T cells, reside in the pancreatic 
lymph node, not directly in the pancreas. The question is how the T cells enter into 
the pancreas.  To answer this question, chemokines and TCR specificity in cell 
trafficking will be discussed.  
 
1.2.3.1 Chemokines and chemokine receptors in T1D 
Chemokines are small proteins that are secreted by many cell types, e.g. osteoblasts, 
endothelial cells, monocytes and macrophages. Concentration gradients are formed 
according to the distance to the source cells. Chemokines attract target cells migrating 
to the source. According to their structural properties, such as the position and number 
of conserved cysteine residues, chemokines have been classified into four subfamilies: 
C, CC, CXC, and CX3C. The X represents any amino acid. So in the CXC subfamily, 
there is an amino acid between the two cysteine, while there are three amino acids in 
the CX3C subfamily.  
 22 
 
Fig 1.2. Chemokines and chemokine receptors (Mantovani  et al., 2006) 
 
Chemokines play important roles in many aspects, such as infection defense, tissue 
damage repair, atherosclerosis, lymph cell homing and autoimmunity. T cell 
infiltration into the pancreas is also chemokine dependent. Frigerio and colleagues 
compared chemokine production in untreated islets and islets exposed to a 
combination of IL-1β, TNF-α and IFN-γ by real-time PCR.  They found the 
chemokines CXCL10, CXCL9, CCL2, CCL5 are highly elevated in the cytokine-
exposed islets (Frigerio et al., 2002). CXCL10 neutralization in the NOD mouse could 
delay diabetes after cyclophosphamide administration (Morimoto et al., 2004).  On 
the contrary, overexpressing CXCL10 in the pancreas under rat insulin promoter (RIP) 
accelerated disease after lymphocytic choriomeningitis virus (LCMV) infection by 
promoting migration of autoreactive T cells into the pancreas (Rhode et al., 2005) 
CCL2 mainly recruits macrophages and B cells into the pancreas. Overexpression of 
 23 
CCL2 under the insulin promoter induces insulitis but no diabetes (Grewal et al., 
1997). This is consistent with the concept that although B cells, monocytes and 
macrophages are the first cell types to infiltrate into the pancreas, T cells are the 
major cells responsible for β cell destruction. 
 
Chemokine receptors belong to the G-protein coupled receptor superfamily, which 
contain seven transmembrane domains. After recognizing the chemokines, the 
activated chemokine receptors activate PI(3)K-Dock2-Rac pathway, inducing cell 
cytoskeleton rearrangement and cell polarization (Weiss-Haljiti C et al., 2004; Viola 
A et al., 2007). So far, several chemokine receptors have been reported in mediating T 
cell trafficking and diabetes pathogenesis. CXCR3 is the receptor for CXCL9 and 
CXCL10. CXCR3 deficient mice are protected from LCMV infection induced 
diabetes (Frigerio et al., 2002). Similarly, CCR5 neutralization did not inhibit insulitis, 
but abrogated β cell destruction and diabetes (Carvalho-Pinto et al., 2004). CCR4 is 
predominantly expressed on Treg and Th2 cells (Lelem et al., 1994; Yagi et al., 2005; 
Curiel et al., 2004; Ishida et al., 2006; Imai et al., 1999). CCR4+ CD4 T cells are more 
potent in inducing insulitis than CCR4- CD4 T cells when transferred into NOD.scid 
mice. Overexpression of macrophage-derived chemokine (MDC, also called CCL22) 
in the pancreas from birth accelerates diabetes (Kim et al., 2002). A recent paper 
reported that β cell-specific overexpression of CCL22 from 8 weeks of age prevents 
disease by recruiting Treg cells into the pancreas (Montane et al., 2011). It is not clear 
whether the opposite conclusions are due to the timing of CCL22 expression in the 
pancreas.
 
Fig 1.3. Chemokines induced cell cytoskeleton rearrangement (Viola A et al., 2007) 
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1.2.3.2 T cell specificity in cell trafficking 
Another question is whether T cell specificity is required when T cells enter the 
pancreas. That is, whether autoreactive T cells that recognize the self antigen in the 
pancreas have priority to enter the pancreas. Fathman and colleagues reported that 
TCR specificity in CD4+ cells was required for disease transfer, illustrated by the fact 
that as few as 500 CD4high T cells isolated from islet, but not from spleen, transferred 
diabetes in CD8+ T cell reconstituted NOD.scid mice (Lejon et al., 1999). A recent 
paper by Lennon and colleagues demonstrated that islet-antigen specificity is required 
for cell infiltration. According to their model, disease development could be divided 
into three stages. At the very early stage. monocytes, macrophages, NK cells and B 
cells enter the pancreas, take up islet antigen and migrate back to the pancreatic 
lymph node. Only T cells bearing islet specific TCR could efficiently get activated, 
expanded and trafficked into the pancreas. Bystander T cells play no role at this stage. 
In the second stage, with increased availability and an array of antigens, T cells that 
harbor a low affinity to islet antigen are activated and recruited. In the last stage, with 
the progress of islet destruction, trafficking becomes antigen-independent. (Lennon, et 
al., 2009) 
 
 
Fig 1.4. Lymph cell infiltration into islet in NOD mouse (Penaranda et al., 2009) 
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1.3 PTPN22 
The human gene PTPN22 is located on chromosome 1p13.3-13.1. PTPN22 encodes 
an intracellular tyrosine phosphatase protein, termed Lyp. In mouse, the species 
homologue gene Ptpn22 encodes the PEST domain-enriched tyrosine phosphatase 
(Pep). Lyp/Pep shares a similar structure, bearing 89% sequence homology in the 
catalytic domain, and 61% homology in the C-terminal domain (Cloutier et al., 1999). 
The conserved proline-rich motif in C-terminal defines Lyp/Pep belonging to the 
phosphatase group -PEST (Cloutier et al., 1996; Cloutier et al., 1999; Vang et al., 
2008). Other members in this group are PTP-PEST and HSC-PTP (Davidson et al., 
1997; Wang et al., 2001). HSC-PTP is exclusively expressed in hematopoietic cells 
and stem cells. PTP-PEST is widely expressed in many cells (Garton et al., 1996; 
Shen et al., 2000). 
 
Lyp/Pep is exclusively expressed in hematopoietic cells, including bone marrow, T 
cells, B cells, as well as myeloid cells (Cloutier et al., 1999; Zikherman et al., 2009). 
In mouse, only one transcript was detected. In humans, three isoforms of Lyp exist 
due to alternative splicing. The longest isoform (Lyp1) encodes a 105kDa protein, 
including N-terminal catalytic PTP domain, and four C-terminal proline-rich motifs. 
The isoform (Lyp2) encodes a small protein (85kDa), which lacks most of proline-
rich motifs (Cloutier et al., 1999). The third isofrom (Lyp3) was reported recently. 
Lyp3 is almost identical to Lyp1, except the 28bp loss in exon 15 (Wang et al., 2010).  
The differential roles of these three isoforms remain to be determined.  
 
Fig 1.5. Three isoforms of Lyp in humans (Wang et al., 2010) 
 
Overexpression of HA-tagged Lyp, or Myc-tagged Pep followed by imunofluorescent 
detection revealed that Lyp/Pep is predominantly cytoplasmic (Cohens et al., 1999; 
Cloutier et al., 1996). 25–50% of Lyp/Pep is constitutively associated with C-terminal 
Src kinase (Csk) (Cloutier et al., 1996). This association requires SH3 domain of Csk 
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and the first proline-rich motif of Pep, especially the eight residue stretch (613–621 
PPPLPERT) (Cloutier et al., 1996; Gjörloff-Wingren et al., 1999). Substrate trapping 
identified substrates for Lyp/Pep. The confirmed substrates include Tyr-394 Lck, Tyr-
417 Fyn, Tyr-493 Zap70, and TCRξ, which reside in the receptor-proximal point. 
Potential substrates are Vav, Valosin containing protein (VCP) and CD3ε. Vav is 
important in cytoskeleton remodeling at the immune synapse, while VCP is involved 
in cell division/survival (Gjörloff-wingren et al., 1999; Cloutier et al., 1999; Wu et al., 
2006).  
 
Lyp/Pep exerts its function in several distinct manners. Lyp/Pep may function alone, 
or together with its partners, c-Cbl and CSK. Lyp/Pep can be recruited to ZAP-70 
through the interactions between SH2 domain of c-Cbl and phospho-Tyr-292 of ZAP-
70 (Kawabuchi et al., 2000). Lyp/Pep could also be enriched in the proximity of Src 
family kinase through the association between SH2 domain of CSK and PAG/Cbp 
(Brdicka et al., 2000).  
 
Fig 1.6. Lyp/pep is a negative regulator in TCR signaling (Burn et al., 2011) 
 
1.3.1 The role of PTPN22 in T cells 
Since most of the substrates for Lyp/Pep are involved in TCR signaling, abundant 
attention has been focused on clarifying the role Lyp/Pep in T cell activation and 
proliferation. As a tyrosine phophatase, Lyp/Pep can dephosphorylate the positive 
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regulatory tyrosine residue in Fyn (Y417), Lck (Y394) and ZAP-70, and thereby 
attenuate T cell activation (Cloutier JF et al., 1999; Gjorloff-Wingren et al., 1999). 
Interestingly, once T cells are activated, the expression of Lyp/Pep is induced (Cohen 
et al., 1999). PTPN22 knockdown by RNAi increases antigen-receptor signaling in 
Jurkat T-cell line (Begovich et al., 2004), while overexpression suppresses T cell 
activation (Cloutier et al., 1999).  
 
Although Lyp/Pep acts as a potent negative regulator in TCR signaling, surprisingly, 
Pep-deficient B6 mice are free from autoimmune disease in spite of some immune 
disorders: 1) the negative selection in the thymus is unaffected, but positive selection 
is a little enhanced in the context of TCR transgene; 2) older Pep-deficient mice 
develop splenomegaly and lymphadenopathy; 3) the effector/memory T cell pool is 
expanded; 4) naïve T cells are unaffected, while effector ⁄memory T cells are 
hyperresponsive to TCR stimulation (Hasegawa et al., 2004). 5) Loss of Ptpn22 
increased thymic Treg cell numbers without affecting the function. More surprisingly, 
although PTPN22 is not a risk factor in multiple sclerosis, the knockout mice are 
protected from EAE, possibly due to the increased Treg cells (Maine et al., 2012). In 
the presence of another risk allele, CD45E613R, Pep-deficient B6 mice develop a 
lupus-like disease, indicating other risk loci are required for disease development in 
B6 mice (Zikherman et al., 2009). 
 
1.3.2 The role of PTPN22 in other cell populations 
Besides T cells, PTPN22 exert important roles in other cells subsets. Increased 
germinal center formation and elevated serum antibody could be found in the Pep-
deficient B6 mice and R619W knockin mice (Hasegawa et al., 2004; Zhang et al., 
2011). In the case of dendritic cells (DCs), CD40 expression is upregulated in R619W 
knockin mice (Zhang et al., 2011). In humans, several reports confirmed that Lyp 
could alter B cell composition and function. Lyp also participates in the removal of 
autoreactive B cells (Menard et al., 2011). Heterozygous subjects for PTPN22 
R620W harbor expanded IgD+CD27- B cells (Habib et al., 2012) as well as decreased 
numbers of memory B cells (IgD+CD27+) in peripheral blood (Rieck et al., 2007). 
BCR signaling is deficient, as illustrated by decreased phosphorylation, calcium flux 
and impaired proliferation (Arechiga et al., 2009).  
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1.3.3 PTPN22 in autoimmune diseases 
Like CTLA-4, PTPN22 is also a general risk factor in the human autoimmune 
disorders. The PTPN22 susceptibility is contributed by a specific SNP (C1858T). 
This SNP results in the substitution from arginine 620(620R) to tryptophan(620W) 
(Bottini et al., 2004). In the mouse, the corresponding replacement is R619W. Lyp-
620W has been demonstrated to be a risk factor in many autoimmune diseases, 
including rheumatoid arthritis (RA) (Orozco et al., 2005; van Oene et al., 2005; 
Wesoly et al., 2005), juvenile idiopathic arthritis (JIA) (Hinks et al., 2005), systemic 
lupus erythematosus (SLE) (Kyogoku et al., 2004), Wegener’s granulomatosis 
(Jagiello et al., 2005), Graves’ disease (Velaga et al., 2004), generalized vitiligo 
(Canton et al., 2005), and T1D (Bottini, et al., 2004; Smyth et al., 2004; Onengut-
Gumuscu et al., 2004). On the contrary, Lyp-620W is a protective allele in Crohn’s 
disease (Frank et al., 2011; Rivas et al., 2011; Diaz-Gallo et al., 2011). In addition to 
autoimmune diseases, PTPN22 is associated with some infectious diseases. Chapman 
and colleagues reported that Lyp-620W was also a risk allele in invasive 
pneumococcal disease (IPD) and Gram-positive empyema (Chapman et al., 2006). 
 
R620W substitution in the P1 motif of PTPN22 disrupts the interaction between Lyp 
and CSK (Bottini, et al., 2004; Vang et al., 2005). The functional consequence of this 
mutation is controversial. Several studies demonstrated that R620W is a gain-of-
function mutation. When the two variants were transfected into Jurkat T cells, Lyp-
620W transfected cells show reduced NF-AT/AP-1 activity. In peripheral blood from 
heterozygous allele carriers, T cells as well as B cells are less responsive, illustrated 
by less phosphorylated proteins, reduced IL-2 production, impaired calcium flux and 
proliferation deficit (Vang et al., 2005; Rieck et al., 2007; Aarnisalo et al., 2008; 
Habib et al., 2012). Most importantly, the response deficit could be reversed by a Lyp 
specific inhibitor (Arechiga et al., 2009; Habib et al., 2012). A model was proposed 
that Lyp and Lck reciprocally inhibit each other. Once TCR is engaged, activated Lck 
phosphorylates Lyp to attenuate Lyp’s function. However, the disease variant Lyp-
620W interrupts the interaction between Lyp and Lck, resulting in decreased 
phosphorylation and elevated Lyp function (Fiorillo et al., 2010). 
 
In contrast, two papers proposed that SNP R620W could be a loss-of-function 
mutation. Zikherman and colleagues used flow cytometry to strictly control the 
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expression levels of the two variants in Jurkat T cells. Intracellular staining for 
phospho-Erk showed Lyp-620W was less potent to dephosphorylate Erk (Zikherman 
et al. 2009). A paper by Siminovitch and colleagues reported that in the Pep-619W 
knockin mice, phenotypes of T and B cells are similar to the Pep knockout mice. 
Further study found that Pep-619W accelerated Pep protein degradation, resulting in 
lower protein levels (Zhang et al., 2011). However, recent findings indicate that the 
enhanced Pep degradation in the knockin mice may be due to the interrupted antibody 
recognition of Pep-619W (Personal communications). Considering the contradictory 
data, more research is required to clarify these conflicting conclusions about the 
outcome of R620W mutation in PTPN22. To characterize the role of Pep in T1D 
within the NOD model, inducible RNA interference (RNAi) was employed in this 
project. 
 
1.4 Inducible RNAi 
Until now, the most conventional method for genetic modification is the knockout 
technique, which has been widely used in mouse strains for which embryonic stem 
(ES) cell are available. First, knockout ES cells must be generated, screened and 
transferred into blastocysts. The surviving blastocysts are then transplanted into the 
uterus of female mice to deliver chimeric mice. The chimeric mice have to be 
backcrossed into the original background to derive homozygous knockout Mice. In 
the case of the NOD mouse, two factors limit the application of this technique. The 
first is the lack of ES cells for the NOD mouse until 2009 (Nichols et al., 2009). So 
far, there is no report using NOD ES cells to generate knockout mice. A possible 
solution is to backcross knockout mice into the NOD genetic background. The second 
difficulty is the genetic complexity in the NOD mouse. More than 20 risk loci, and 
dozens of gene variations are implicated in disease onset in the NOD mouse. When 
backcrossing knockout mice into the NOD background, it is very likely that in 
addition to the target gene, unexpected genome fragments will also be introduced. For 
example, in the NOD mouse, Ptpn22 is located in Idd region 18.2 on chromosome 3. 
On the same chromosome, Idd10 and Idd18.1 are close to Ptpn22. During the 
backcross, protective B6 gene segments may replace susceptibility genes in Idd10, 
Idd18.1 and Idd18.2, resulting in the incorrect understanding of Ptpn22 effect in T1D.  
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To functionally study the role of Ptpn22 in the pathogenesis of T1D in the NOD 
mouse, we decided to examine the mouse phenotype when Ptpn22 is inducibly 
silenced. Compared to conventional RNAi, inducible RNAi possesses several 
advantages. First, the knockdown can be initiated at any time, which is valuable when 
loss of protein is lethal; second, protein expression can be recovered after terminating 
gene knockdown, which is useful to study phenotype recovery or duration; last, 
knockdown efficiency can be controlled by different concentrations of inductive 
material, which is essential to study the effect of gradient TCR/BCR signaling 
strength on diverse cell populations. 
 
The figure below explains how the inducible knockdown works. The system contains 
two promoters. shRNA expression is controlled by an RNA polymerase ΙΙΙ promoter 
(H1 promoter) containing a tetracycline operator (TetO). The ubiquitin promoter 
expresses the tetracycline repressor (TetR) and GFP in all the transfected cells. In the 
absence of doxycycline (Dox), TetR binds to the tetracycline operator (TetO), 
blocking shRNA expression. Dox addition in water or food removes TetR from TetO, 
so that the H1 promoter can transcribe shRNA to induce knockdown (Herold et al., 
2008). 
 
Fig 1.7. Inducible RNAi based on Tetracycline on/off system (Herold et al., 2008) 
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1.5. Lentiviral transgenesis 
Gene knock down can be achieved by siRNA or shRNA. The main disadvantage of 
using siRNA is the dilution effect (Kim et al., 2007). Once siRNA enters into cells, it 
cannot be replicated by host cells. During cell division, siRNA concentration will be 
too low to maintain knockdown. In in vitro experiments, siRNA has to be 
retransfected every 2-3 days. To achieve the sustained knockdown in vivo, RNAi 
based on lentiviral transgenesis was used. Lentiviral vectors provide an alternative 
tool for transgenesis. Lentiviral vectors derive from immunodeficiency viruses, such 
as HIV-1. Lentiviral vectors have the capability to incorporate into genomic DNA 
with high efficiency and long-time duration, in both dividing and non-dividing cells. 
The preferred integration sites are within intergenic sequences, especially in introns, 
which means lentiviral integration is unlikely to interrupt endogenous gene function 
(Yang et al., 2008). 
 
Lentiviral vectors underwent important modifications to improve their safety and 
gene-transfer efficacy. First, lentiviral vectors were engineered to lose the ability for 
self-replication. Self-replication components are separated in different vectors. 
Second, some important DNA elements were added, such as a central poly purine 
tract sequence (cppt) to enhance the transduction efficacy, woodchuck post regulatory 
element (WPRE) to stabilize the transcript. Besides, some insulators or 
matrix/scaffold attachment regions (MAR/SAR) were added to reduce the chance of 
viral silencing. Last, a 400 bp deletion in the  3’-LTR known as “self-inactivation 
(SIN)” was performed to prevent transcription from the endogenous LTR internal 
promoter. Hence, lentiviral vectors have become an appealing method to establish 
transgenic mice and to manipulate the mammalian genome, especially in ES-deficient 
mouse strains.   
 
In our study, five plasmids were used to generate lentivirus for gene delivery: transfer 
vector, Gag-pol, Rev, VSV-G and pAdvantage (Pernod et al., 2004; Singer et al., 
2008). Target shRNA was cloned into the transfer vector, which contains Rev 
responsive element (RRE). Gag-pol encodes reverse transcriptase, integrase and 
structural proteins. Rev interacts with RRE in the transfer vector to increase virus 
titers by enhancing nuclear export of viral RNA. VSV-G (Vesicular Stomatitis Virus 
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protein G) codes for viral envelope proteins, which broaden host cell types. 
pAdvantage encodes an inhibitor for interferon-induced protein kinase (PKR), that 
increases lentivirus titers. Five plasmids were cotransfected into 293 F cells to 
generate lentivirus. Lentivirus carrying inducible shRNA was injected into the 
perivitelline space of single cell embryo to obtain transgenic NOD mice.  
 
1.6. Aim of study 
As mentioned above, Lyp-620W confers susceptibility in many human autoimmune 
diseases. So far, whether the R620W allele is a gain- or loss- of function remains 
controversial. Therefore, in this project we aimed to  
 
1) explore if Lyp-620W is a gain- or loss-of-function variant by studying the role of 
Pep in T1D and colitis in the NOD mouse. Furthermore, by using the inducible 
knockdown system, Ptpn22 was silenced in the adult mice when most thymocytes are 
matured to better mimick the therapy in humans. 
2) functionally study the role of Pep in different cell populations (Treg cells, 
regulatory B cells); 
3) examine the role of Pep on chemokine receptors. Chemokine receptors are crucial 
for lymph cell trafficking into pancreatic islets. So far, a lot of attention was paid on 
the role of Lyp/Pep in naïve, effector T cells and antigen presenting cells (B cells, 
DCs). It is totally unknown weather Pep regulates chemokine receptor expression. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 Materials 
 
2.1.1 Chemicals and reagents 
 
Chemicals/reagents Source Application 
10X Dreamtaq buffer Fermentas PCR 
10X T4  ligase buffer Fermentas  
19G, 27G needles Neoject Tissue digest 
1ml, 20ml, 30ml syringe Terumo Tissue digest 
24 well plate BD Cell culture 
4X laemmli buffer Roth Western blot 
6 well plate BD Cell culture 
Absolute Blue SYBR Green 
ROX mix Thermo Scientific RT-PCR 
acrylamide solution (30%) Biorad  
Agarose Roth  
Ammonium persulfate (APS) Roth  
Ampicillin Roth  
BbsI New England Biolabs Restriction digest 
Beta mercaptoethanol Roth  
Beta mercaptoethanol GIBCO Cell culture 
Biotinylated protein ladder Cell signaling technology  
Brefeldin A Sigma Intracellular staining 
Bromophenol blue Roth  
BSA Sigma Solution preparation 
BSA New England Biolabs Pancreas digestion 
Buffer 1 New England Biolabs Restriction digest 
Buffer 2 New England Biolabs Restriction digest 
Buffer 4 New England Biolabs Restriction digest 
CaCl2 Roth  
Calf intestinal alkaline 
phosphtase (CIAP) Fermentas  
Chloroform Roth  
Compensation beads BD  
Complete Freund’s adjuvant  Sigma In vivo priming 
Cyclophosphamide.H2O (CY) Sigma Diabetes induction 
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Dimethyl sulfoxid (DMSO) AppliChem  
DNA ladder (1Kb plus) Fermentas  
DNA ladder (low range) Fermentas  
DNase I Roche Pancreas digestion 
dNTP Fermentas  
Doxycline hydrate (Dox) Sigma RNAi induction 
D-PBS GIBCO  
Dreamtaq polymerase Fermentas PCR 
Dynabeads mouse T activator 
CD3/CD28 Invitrogen  
ECL Perkin Elmer  
EDTA Roth  
eFluor® 670 
 
eBioscience  
 
Cell proliferation 
tracer 
Elisa 96 well plate (maxi sorp) Nunc Elisa assay 
Ethanol Roth  
Ethidium bromide Roth  
Fetal calf serum (FCS) GIBCO  
Fugene HD Roche Transfection 
Genejammer Agilent (Stratagene) Transfection 
Glutamine GIBCO  
Glycerol Roth  
Glycine Roth  
H2SO4 Roth  
H3-thymidine Hartmann Analytic  
HEPES GIBCO Cell culture 
Human chorionic gonadotropin 
(HCG) 
 
Sigma  
HybondTM-N+ membrane Amersham GE Healthcare,UK  
Ionomycin Sigma  
Isofluran Cp-pharma  
Isopropanol Roth  
KCl Roth  
KHCO3 Roth  
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LD column Miltenyi Biotech  Cell isolation 
Liberase TL Roche Pancreas digestion 
LPS Sigma  
LS column Miltenyi Biotech  Cell isolation 
Methanol Roth  
MgCl2 Roth  
MgCl2 Fermentas  
MicroAmp clear adhesive film Applied Biosystems  
MOG peptide Biotrend  
MS column Miltenyi Biotech  Cell isolation 
Na2-EDTA Roth  
Na2HPO4 (2H2O) Roth  
NaCl Roth  
NaH2PO4 (H2O) Roth  
NaHCO3 Sigma  
NaOH Roth  
NH4Cl Roth  
Nitrocellulose membrane BioRad  
PacI Fermentas Restriction digest 
Passive lysis buffer Sigma-Aldrich  
Penicillin streptomycin solution Invitrogen  
Pertussis toxin Sigma  
Phorbol myristate acetate 
(PMA) Sigma  
PMS hormone Sigma  
PNK Fermentas  
Polybrene Sigma Transfection 
Polyfect Qiagen Transfection 
Primer-probe pair Universal probe library, Roche  
Protein ladder BioRad  
rhIL-2 R&D  Treg cell expansion 
rhTGF-β R&D T cell differentiation 
RNA later Qiagen  
RNase A Qiagen  
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RT-PCR plate (384 well clear 
optical) Applied Biosystems  
SDS Roth  
Sodium citrate Sigma  
Sodium pyruvate GIBCO Cell culture 
T4 DNA ligase Fermentas  
TE buffer Fluka Analytical  
TEMED BioRad  
Tris Roth  
Tris-HCl Roth  
Trizol Invitrogen RNA extraction 
Trypsin GIBCO  
Tween20 Roth  
U-100 insulin syringe Terumo Mouse injection 
U-bottom 96 well plate BD Cell culture 
Ultra-clear centrifuge tube Beckman Virus centrifuge 
Universal probe master mix 
(ROX) Roche RT-PCR 
V-bottom 96 well plate Nunc Cell staining 
Whatman paper VWR  
XhoI Fermentas Restriction digest 
X-ray film Fujifilm  
 
 
2.1.2 Medium 
 
Medium Recipe Application 
DMEM 
Advanced DMEM 
(invitrogen, #12491) plus: 
10% heat inactivated FCS, 
Penicillin-Streptomycin  
 
293-F cell culture 
RMPI 
RMPI 1640 (invitrogen, 
#51875) plus: 
10% heat inactivated FCS, 
Penicillin-Streptomycin, 
1mM Sodium pyruvate 
50uM 2- mercaptoethanol 
10mM Hepes 
T, B and DC culture 
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2.1.3 Buffer 
Buffer Supplier/recipe Application 
0.4% Trypan blue buffer Invitrogen Cell counting 
10X PBS Invitrogen Buffer/solution preparation 
10X SDS running buffer 
10g SDS, 30.3g Tris and 
144.1g glycine in 1L dd 
H2O distilled water.  
Western blot 
1X PBS Invitrogen Cell culutre 
ACK buffer 
8.29g ammonium chloride, 
1.0g potassium 
bicarbonate and 37.3 mg 
Na2EDTA  
in 800ml distilled H2O. 
Adjust the pH to 7.2-7.4 
and fill up to 1L with  
distilled H2O.   
 
Lysis of red blood cells 
Annexin V binding buffer  
 
10mM Hepes (2.38g/L), 
150mM NaCl (8.766g/L), 
5mM KCl (0.372g/L), 
1mM MgCl2 (0.203g/L) 
and 1.8mM CaCl2 
(0.199g/L). Adjust pH to 
7.4 with NaOH. 
 
Annexin V staining 
Blocking solution (5%)  
 
5g nonfat dried milk 
powder in 100ml 0.2% 
TBST buffer  
 
Membrane block in 
western blot 
Cell depletion buffer 
0.1% FCS (0.5ml) and 
2mM EDTA (0.3722 mg) 
in 1X PBS (500ml, 
Invitrogen). 50°C  for 4-5 
hours or RT overnight. 
Buffer is filtered and 
stored at 4°C  
Cell depletion with 
invitrogen dynalbeads 
FACS buffer 
5ml heated inactivated 
FCS in 500ml PBS. Stored 
at 4°C  
FACS staining 
LB medium with Ampr 
10g Trypton, 10g yeast 
extract and 5g sodium 
chloride in 1L distilled 
water. Adjust pH to 7.0 
with sodium hydroxide. 
After autoclaved and 
cooling down 50-55°C , 
add 50µg/ml Ampicillin 
(50ml/ml in 50% EtOH) 
 
Bacteria culture 
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LB plate 
Add 8g agar into LB 
medium (without 
antibiotics). After 
autoclaved and cooling 
down 50-55°C , add 
100µg/ml Ampicillin, or 
50µg/ml Kanamycin 
(50ml/ml in 50% EtOH) 
Cloning 
MACS buffer 
0.5% FCS (2.5ml) and 
2mM EDTA (0.3722 mg) 
in 1X PBS (500ml, 
Invitrogen). 50°C  for 4-5 
hours or RT overnight. 
Buffer is filtered and 
stored at 4°C  
Cell separation with 
MACS Kits 
P1 buffer 
(resuspension buffer) 
50mM Tris-HCl (6.06g) 
and 10mM EDTA(3.72g 
Na2EDTA 2H2O) in 800 
ml distilled water. Adjust 
pH to 8.0 with HCl and fill 
up to 1L. Finally add 
100mg (100µg/ml) 
RNaseA 
Miniprep 
P2 buffer 
(lysis buffer) 
200mM NaOH (8g) and 
1% SDS(50ml 20% SDS 
w/v) in 1L distilled water 
Miniprep 
P3 buffer 
(neutralisation buffer) 
3M Potassium-Acetate 
(294.5g)  to pH5.5 with 
acetic acid, fill up to 1 liter 
Miniprep 
PBS/EDTA 
2mM (0.3722mg) EDTA 
in 500 ml PBS. 50°C  for 
4-5 hours or RT overnight. 
Buffer is filtered and 
stored at 4°C  
 
For tail blood collection 
TBST (0.2%)  
 
50mM Tris (6.05g) and 
150mM NaCl (8.76g) in 
800 ml distilled water. 
Adjust pH to 7.5 and fill 
up to 1L. Finally add 2ml 
Tween 20 
 
Membrane wash in 
western blot 
Transfer buffer 
2.9 g glycine, 5.8 g Tris 
and 0.37 g SDS in 800ml 
distilled water. Adjust the 
volume to 1L with 200ml 
methanol 
Western blot 
Wash buffer  
200ml 10X PBS in 1.8L 
distilled water. Add 1ml 
Tween20 (0.05%) 
ELISA assay 
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2.1.4 Kits 
 
Kit Supplier Application 
BCA protein assay kit Novagen Measuring protein conc 
CBA kit BD Cytokine measurement by FACS 
CCL17 elisa kit R&D Elisa assay 
CCL22 elisa kit R&D Elisa assay 
CD11c + MACS separation 
kit Miltenyi Biotech  
DC isolation 
CD19 MACS separation kit Miltenyi Biotech  B cell isolation 
CD4+CD25+ MACS 
separation kit Miltenyi Biotech 
Treg cell isolation 
CD4+CD62L+ MACS 
separation kit Miltenyi Biotech 
Naïve/effector T cell 
isolation 
CD43 MACS separation kit Miltenyi Biotech B cell isolation 
DNeasy blood and tissue kit Qiagen   DNA extraction 
FoxP3 staining kit eBioscience   Foxp3 staining 
QIAfilter Plasmid Maxi kit Qiagen Plasmid for virus production 
QIAquick Gel Extraction kit Qiagen   DNA purification from gel 
QIAquick PCR purification 
kit 
Qiagen  
 
DNA purification from 
buffer 
Ready-Set-Go Elisa kit eBioscience   Cytokine measurement 
RNeasy kit Qiagen   RNA extraction 
Transcriptor first strand 
DNA synthesis kit 
Roche  
 cDNA synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
2.1.5 Bacteria and cell line 
 
Bacteria: 
Bacteria Supplier Application 
DH5α Invitrogen   Transformation and cloning 
MAX EfficiencyDH5α Invitrogen   Transformation and cloning 
Novablue 
Invitrogen/ Merck/ 
Novagen  
 
Transformation and cloning 
One Shot TOP10 Invitrogen   Transformation and cloning 
 
Cell line: 
293 F cell line: is also called HEK 293 cell line. It is established from human 
embryonic kidney cells transformed with sheared adenovirus 5 DNA. 293 F cells are 
easy to culture and transfect. In this project, 293 F cells were used to generate 
lentivirus. 
 
2.1.6 shRNA Sequences against Ptpn22 
 
P1 (position 321): target-GTAGAGCTGTCTCTGTTAA 
Fwd:  
TGTAGAGCTGTCTCTGTTAATTCAAGAGATTAACAGAGACAGCTCTACTTTTTTC 
Rev: 
TCGAGAAAAAAGTAGAGCTGTCTCTGTTAATCTCTTGAATTAACAGAGACAGCTCTACA 
 
P2 (position 345): target-GATGAGGATTCCAGTTATA 
Fwd:  
TGATGAGGATTCCAGTTATATTCAAGAGATATAACTGGAATCCTCATCTTTTTTC 
Rev: 
TCGAGAAAAAAGATGAGGATTCCAGTTATATCTCTTGAATATAACTGGAATCCTCATCA 
 
P3 (position 1421): target-GGACAGGTATCACAATTCA 
Fwd:  
TGGACAGGTATCACAATTCATTCAAGAGATGAATTGTGATACCTGTCCTTTTTTC 
Rev: 
TCGAGAAAAAAGGACAGGTATCACAATTCATCTCTTGAATGAATTGTGATACCTGTCCA 
 
P4 (position 1682):  target-GCATCTGTACACATCTTTA 
Fwd:  
TGCATCTGTACACATCTTTATTCAAGAGATAAAGATGTGTACAGATGCTTTTTTC 
Rev: 
TCGAGAAAAAAGCATCTGTACACATCTTTATCTCTTGAATAAAGATGTGTACAGATGCA 
 
P5 (position 2285): target-GAACTCCACATCTTCTAAA 
Fwd:  
TGAACTCCACATCTTCTAAATTCAAGAGATTTAGAAGATGTGGAGTTCTTTTTTC 
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Rev: 
TCGAGAAAAAAGAACTCCACATCTTCTAAATCTCTTGAATTTAGAAGATGTGGAGTTCA 
 
P6 (position 2562): target-GCAGATAAAGCTACTTGAA 
Fwd:  
TGCAGATAAAGCTACTTGAATTCAAGAGATTCAAGTAGCTTTATCTGCTTTTTTC 
Rev: 
TCGAGAAAAAAGCAGATAAAGCTACTTGAATCTCTTGAATTCAAGTAGCTTTATCTGCA 
 
P7 (position 2578): target-GAATACTGCTATAATAATA 
Fwd:  
TGAATACTGCTATAATAATATTCAAGAGATATTATTATAGCAGTATTCTTTTTTC 
Rev: 
TCGAGAAAAAAGAATACTGCTATAATAATATCTCTTGAATATTATTATAGCAGTATTCA 
 
P8 (position 2639): target-GAAAGCAATATGTGACAAA 
Fwd:  
TGAAAGCAATATGTGACAAATTCAAGAGATTTGTCACATATTGCTTTCTTTTTTC 
Rev: 
TCGAGAAAAAAGAAAGCAATATGTGACAAATCTCTTGAATTTGTCACATATTGCTTTCA 
 
2.1.7 Antibodies 
 
Antigen FC Company Clone Dilution 
Actin  Sigma   
Annexin V APC BD  1:100 
Annexin V PE BD  1:100 
ArmHamster IgG1 Purified/FG BD G94-56  
B220 (CD45R) APC BD RA3-6B2 1:300 
B220 (CD45R) PE BD RA3-6B2 1:300 
B220 (CD45R) APC eFluor 780 eBioscience RA3-6B2 1:400 
CD103 PerCP-Cy5.5 BioLegend 2E7 1:400 
CD11b PECy7 BD MI/70 1:800 
CD11b eFluor 450 eBioscience MI/70 1:1600 
CD11c PECy7 BD HL3 1:1600 
CD16/32 
(FcgR3/2) 
Purified/FG eBioscience 93 1µl/ 1x106 cells 
CD19 eFluor 450 eBioscience 1D3 1:1600 
CD23 PE eBioscience B3B4  
CD25 PECy7 BD PC61 1:300 
CD25 PerCP-Cy5.5 BioLegend PC61 1:300 
CD25 APC eBioscience PC61.5 1:300 
CD25 PerCP-Cy5.5 eBioscience PC61.5 1:300 
CD25 Purified/FG eBioscience PC61.5  
CD273 (B7-DC) PE BD TY25 1:800 
CD274 (B7H1) PE BD MIH5 1:800 
CD28 Purified/FG BD 37.51  
CD28 Purified/FG eBioscience 37.51  
CD3ε FITC BD 145-2C11  
CD3ε PE BD 145-2C11 1:300 
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CD3ε PerCP BD 145-2C11 1:200 
CD3ε V500 BD 500A2 1:800 
CD3ε PerCP-Cy5.5 BioLegend 145-2C11 1:400 
CD3ε Brilliant Violet 
421 
BioLegend 145-2C11 1:400 
CD3ε Purified/FG eBioscience 145-2C11  
CD3ζ PE Cedarlane Cl7230  
CD4 Alexa 647 BD RM-4-5 1:400 
CD4 APC-Cy7 BD GK1.5 1:800 
CD4 PerCP-Cy5.5 BD RM4-5 1:800 
CD4 V500 BD RM4-5 1:1600 
CD4 Brilliant Violet 
421 
BioLegend GK1.5 1:800 
CD4 APC eBioscience RM4-5 1:800 
CD4 Purified/FG eBioscience GK1.5  
CD40 Purified/FG eBioscience HM40-3 1:800 
CD40L (CD154) PE BD MR1  
CD44 FITC BD IM7  
CD44 PECy5 BD IM7 1:3000 
CD45 eFluor 780 eBioscience 30-F11 1:400 
CD45RB PE eBioscience C363.16A 1:1600 
CD49b/Pan NK FITC BD DX5  
CD5 PE BD 53-7.3 1:300 
CD62L FITC BD MEL-14  
CD62L PE BD MEL-14 1:200 
CD62L APC-Cy7 BioLegend MEL-14  
CD69 PECy7 eBioscience H1.2F3 1:300 
CD8 PE-Cy7 BioLegend 53-6.7  
CD80 Biotin BD 16-10A1  
CD80 APC eBioscience 16-10A1 1:1600 
CD86 Biotin BD GL1  
CD86 APC eBioscience GL1 1:1600 
CD86 PE eBioscience GL1 1:1600 
CD8a APC BD 53-6.7 1:800 
CD8a PE BD 53-6.7 1:800 
CD8a PECy7 BD 53-6.7 1:800 
CD8a eFluor 450 eBioscience 53-6.7 1:1600 
CD93 (AA4.1) APC eBioscience AA4.1  
CTLA-4 (CD152) PE BD UC10-4F10-
11 
1µg intrac 
CTLA-4 (CD152) PE eBioscience UC10-4B9 1µg intrac 
F4/80 PECy5 eBioscience BM8 1:400 
F4/80 APC eBioscience BM8  
Foxp3 APC eBioscience FJK-16s  
Foxp3 PE eBioscience FJK-16s  
GITR APC eBioscience DTA-1 1:300 
GITR-L Biotin eBioscience eBio 
YGL386 
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goat IgG PE Santa Cruz   
I-Ab PE BD AF6-120.1  
I-Ak Biotin BD 10-3.6  
ICAM-1 (CD54) PE BD 3E2  
IgD PE BD 11-26c.2a  
IgM PE-Cy7 BD R6-60.2 1:200 
IgM F(ab)’2 purified Jackson Immuno 115-006-020  
Klrg1 (MAFA) PE BioLegend 2F1/KLRG1 1:400 
PLC-γ2 (pY759) PE BD   
PEP (Ptpn22)  From Dr. Chan   
PI Purified/FG BD  1µl/ 1x106 cells 
rat IgG1 κ APC BD   
rat IgG1 κ PE BD   
rat IgG2a APC eBioscience eBR2a  
rat IgG2a Biotin eBioscience eBR2a  
RT1B (I-Ag7) PerCP BD OX-6 1:800 
SA APC BD   
SA PE BD   
SA PerCP-Cy5.5 BD   
TCRβ APC BD H57-597 1:300 
TCRβ Biotin BD H57-597  
TCRβ APC eFluor 780 eBioscience H57-597  
TCRβ PerCP-Cy5.5 eBioscience H57-597 1:300 
tetR  Mobitec   
Zap70 pY319 Alexa 647 BD 17A/P-
ZAP70 
 
 
2.2 Methods  
2.2.1 293 F cell passage 
The 293 F cell line is derived from human embryonic kidney cells, which is maintained 
in advanced DMEM medium supplemented with 5% FCS, glutamine and penicillin/ 
streptomycin (P/S) in 10 cm plates. The plates are maintained in the incubator at 
37°C with 5% CO2. After 3-day growth, exhausted medium is aspirated; cells are 
washed with 10ml PBS and then treated with 1ml trypsin for 2-3min. 9 ml media is 
then added to inactivate trypsin as well as to suspend cells. 1 ml cell suspension is 
added into new plates containing 9 ml fresh medium.  
 
2.2.2 Cloning of inducible shRNA expression vector  
Dr. Stephan Kissler had previously tested knock down efficiencies of 8 shRNAs in 
 45 
the pLB backbone. Luciferase reporter assay demonstrated that shRNA P2 and P4 
displayed the highest knock down efficiency. These two shRNA sequences were 
cloned into the inducible shRNA expression vector FH1t-UTG (kindly provided by 
Dr. MJ Herold). The inducible shRNA expression system consists of 2 vectors, 
pH1tet-flex and FH1tUTG. shRNAs are synthesized, phosphorylated and cloned into 
pH1tet-flex vector. The fragment containing the H1 promoter and tet-operator is cut 
and inserted into the final vector, FH1tUTG.  
 
                       A 
pH1tet-f lex
3301 bp
amp
H1-tetO promoter
Xh oI (384)
SalI (1)
AscI (413)
MfeI  (6)
MluI  (390)
EcoR I (1 37)
BbsI (361)
Xba I (378)
M13 reverse (-49) (100.0%)
oRNA 48 (100.0%)
 
                     B 
FH1t(INSR)UTG
10963 bp
eGFP
WPRE Intron
CMV-LTR
LTR
HIV-RRE
Sense IR5
Antisense IR5
Spacer
T2A-Peptide
cPPT
Ubiquitin-P
HI-TetO Promotor
Exon
hTetR
Mlu I (232)
Pac I (2599)
Pac I (2951)
Avr II (3901)
Avr II (8007)
 
Fig 2.1 : Schematic diagram of the inducible shRNA expression system.  
A: pH1tet-flex vector, B: FH1tUTG vector 
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First, forward and reverse oligos with BbsI and XhoI overhangs were synthesized 
(Sigma) and dissolved in ddH2O at 100pmol/µl. Oligo phosphorylation is done in the 
following reaction condition: 
6µl            oligos 
1µl            PNK 
1µl            T4 ligase buffer 
2µl            ddH2O 
37°C for 1 hour. 
 
Phosphorylated fwd and rev oligos were annealed in the PCR machine using the 
following conditions: 94°C 2min, 70°C 5min, and 4°C 10min. The annealed oligos 
were diluted in 600µl ddH2O.  
 
To insert shRNA oligos behind the human H1 promoter containing a tet-operator in 
the pH1tet-flex vector, the vector was digested with BbsI and XhoI: 
30µl (3µg)   pH1tet-flex        
2µl               BbsI  
1µl               XhoI                    
0.5µl            BSA                     
5µl               NEB buffer 2       
11.5µl          ddH2O                   
37°C for 1.5 hour. 
 
The digested DNA fragment was purified by Qiaquick PCR purification kit. Purified 
vector was ligated with annealed oligos: 
10µl (3µg)   digested pH1tet-flex        
1µl               diluted oligos                  
2µl               T4 ligase buffer                     
1µl               T4 ligase       
6µl               ddH2O                   
22°C for 2 hour. 
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The ligation products were used to transform DH5α competent bacteria. Competent 
bacteria were thawed on the ice, and then incubated with ligation product for 30min. 
Bacteria were heat-shocked at 42°C for 90s, and then kept on ice for 5min prior to 
being plated out. The positive clones are selected on ampicillin LB agar plates. 
Besides the positive clones, self-ligated vector without insert could also grow in the 
presence of ampicillin. To screen for positive clones, 10 clones for each construct 
were picked and cultured in 3ml ampicillin containing LB medium for 6-7h to prepare 
the miniprep.  
 
2.2.3 Miniprep 
Miniprep was used to isolate plasmid DNA from bacteria in a small scale. Miniprep 
was performed with P1, P2 and P3 buffers prepared in the laboratory (recipes 
mentioned in material section). Bacteria suspensions were transferred into eppendorf 
tube and spun down at 13000rpm for 5min to harvest bacteria. The pellet was 
resuspended at 150µl P1, followed by addition of 150µl P2, inverting several times, 
and incubating at RT for 2min. 150µl P3 was then added. The mixture was 
centrifuged at 13000rpm for 5min. The supernatant was transferred into a new 
eppendorf tube. 300µl isopropanol was added to precipitate plasmid DNA by 
centrifuging at 13000rpm for 10min. The DNA pellet was washed with 500µl 70% 
ethanol. DNA is air dried and dissolved in 30-50 µl ddH2O. 
 
The plasmid DNA was digested using restriction enzyme to screen the positive 
clones. In this case, when PacI enzyme was used, positive and negative clones should 
generate a 300bp and 23bp band, respectively.  
 
42.5µl (24µg)    pH1tet-flex DNA  
2µl                     PacI 
5µl                     NEB buffer1 
0.5µl                  10X BSA 
37°C for 2 hour. 
In parallel, 5µg FH1tUTG vector was digested with PacI in the same condition.  The 
reaction products are run in 1% agarose gel. FH1tUTG backbone and 300bp band 
from pH1tet-flex are cut and purified by Qiaquick gel purification kit, followed by 
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ligation, and transformed into component DH5α bacteria to prepare plasmid DNA by 
miniprep. The positive clones were screened by XhoI digest, and further sequenced 
with primer FUW1 (GACATAATAGCAACAGAC) to make sure the shRNA 
sequence is correct. 
 
2.2.4 Luciferase reporter assay  
To further validate that the shRNA sequence is correct, a luciferase reporter assay 
with psi-check2 vector was used to measure shRNA knockdown efficiency. In this 
dual luciferase vector, firefly luciferase is constitutively expressed and used to 
normalize data to the transfection efficiency. Ptpn22 cDNA was inserted behind 
renilla luciferase mRNA, into the 3’ UTR. The principle is if the shRNA works 
efficiently, the fusion mRNA will be degraded, resulting the reduction of renilla 
luciferase signal. Thus, the reduction of renilla luciferase should be an indicator of 
shRNA knock down efficiency.  
 
In this assay, 2.5 x 105 293F cells were plated on a 24-well plate. The following day, 
cells were co-transfected with 100 ng psi-check 2 containing Ptpn22 cDNA, 300 ng 
shRNA constructs and 3 µl Genejammer. After 1 day, supernatant was aspirated and 
cells were washed once with 200 µl PBS. Cells were lysed with 150 µl passive lysis 
buffer at RT for 5min. 5 µl lysate was added into an opaque 96-well plate to measure 
firefly and renilla luciferase with a Fluostar Optima luminometer.  
 
2.2.5 Maxiprep 
The maxiprep was used to get a large amount of plasmid DNA for lentivirus 
production. Bacteria with correct P2 or P4 shRNA plasmid were grown in 100 ml 
ampicillin containing LB medium overnight. The maxiprep was performed with a 
Qiagen maxiprep kit according to the manufacturer’s instructions. In principle, 
bacteria were lysed and neutralized. DNA bind to anion exchange resin under low salt 
and pH condtion and further washed by high salt buffer. Finally, DNA was dissolved 
in TE buffer at the concentration of 1µg/µl. 
 
2.2.6 Lentivirus production and titration 
Once a large amount of DNA was obtained by maxiprep, lentivirus was produced to 
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generate transgenic mice. To generate lentivirus, 8-9 x 106 293 F cells were plated in 
20 cm plate. The next day, 3µg pCMV-VSVg, 3µg RSV-rev, 4µg pMDL-gag/pol, 
5µg pAdvantage, 20µg shRNA construct along with 70µl Fugene HD were added into 
2ml serum free media. The mixture was incubated at room temperature for 30 
minutes, and then added onto cells. 2 days after transfection, supernatant was 
collected, spun down at 2300rpm for 7min and filtered. Viral medium was then 
ultracentrifuged at 25000rpm for 90min. The supernatant was carefully aspirated. 
100µl PBS was added along the tube. The virus was recovered by overnight 
resuspension at 4°C. The next day virus was carefully resuspended, and aliquoted into 
4tubes. The tubes were flash-frozen in liquid nitrogen and stored at -80°C.  
 
Only lentivirus with high titers was used to inject single cell embryo. To titrate 
lentivirus, 4 x 105 293 F cells were plated into 6 well plates the day before titration. 
1µl lentivirus is added into 1ml DMEM medium, and then further serially diluted to 
1:10 and 1:100. After 1-day infection, supernatant is removed. Cells were washed 
twice with 1ml PBS, and then transferred into FACS tube. The percentage of GFP+ 
cells is recorded by FACS CantoΙΙ. 
 
2.2.7 Generation of lentiviral transgenic NOD mice  
No ES cells were available in the NOD background until very recently (Nichols et al., 
2009). To generate transgenic NOD mice, single cell NOD embryos were employed. 
Female mice were injected with pregnant mares serum (PMS), 48 hours later followed 
with human chorionic gonadotropin (HCG). Females were then mated with males 
overnight. The next morning, females were dissected to obtain oviducts. Single cell 
embryos were collected under a microscope.   
  
Lentivirus with high titers (>1x108 particles/ ml) was injected into the perivitelline 
zone of embryos. Infected embryos were then implanted into pseudopregnant females 
to deliver transgenic pups. Since P2/P4 shRNAs were used to inducible knock down 
Ptpn22, transgenic mice carrying P2 and P4 shRNA are termed P2 and P4 mice, 
respectively. 
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2.2.8 Mouse genotyping 
In the shRNA expression cassette, the ubiquitin promoter constitutively expresses 
GFP. Thus, GFP is a good indicator for transgenic mice. After pups were weaned, 
blood samples were collected from tail cut. Blood was treated with ACK buffer to 
remove red blood cells. Cells were washed twice with PBS 1% FCS, and then 
analysed by FACS to check the GFP expression in the lymphocytes.  
 
2.2.9 Mouse treatment 
Transgenic P2/P4 mice were treated with 200 µg/ml Doxycycline (Dox) to knock 
down Ptpn22. Meanwhile, WT and some P2/P4 mice were left untreated to test for 
leaky shRNA expression without Dox. Some WT mice were also treated with Dox to 
examine the effect of Dox in non-transgenic mice.  
 
2.2.10 Knock down validation by qRT-PCR and western blot 
When mice were 5-7 weeks old, they were treated with Dox for 7-10 days. Mice were 
then dissected to obtain lymph nodes. Lymph cells were treated with ACK buffer, 
filtered to make single cell suspensions. Lymph cells were used to prepare samples 
for qRT-PCR and western blot to validate knock down on the mRNA and protein 
levels. 
 
qRT-PCR: 
Total RNA was obtained using Qiagen RNeasy kit following manufacturer’s 
instructions. cDNA was synthesized with a first strand cDNA synthesis kit from 
Roche. For each reaction: 
1µg                               Total RNA                                                           
1µl (2.5µm)                  Anchored-oligo dT 18 primer                              
2µl (60µm)                   Random hexames primers                                    
variable                        H2O                                                                       
13µl                              Total volumn                                                         
 
The mixture was heated at 65°C for 10min, immediately cooled on ice. Adding master 
mix containing: 
4µl                                RT buffer 5X                                                        
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0.5µl                             DNase inhibitor                                                    
2µl                                DNTP mix (10mM each)                                      
0.5µl                             Reverse transcriptase (20U/µl)                         
      
The 20 µl mixture was left in the PCR machine using program 25°C 10min, 55°C 
30min, 85°C 5min and then 4°C forever. cDNA is diluted with H2O to 1:3. qRT-PCR 
is done with Taqman probe and universal probe master mix (ROX) from Roche. The 
primer sequences and probe are as follows:  
GAPDH: fwd 5’- agcttgtcatcaacgggaag-3’, rev 5’-tttgatgttagtggggtctcg- 3’, probe: #9 
PTPN22: fwd 5’- cagaacgtgttcagccaaaa-3’, rev 5’-ttggtcctttgcgttttgaa- 3’, probe: #17 
 
The PCR was performed in 384-well plates. For each reaction: 
5µl                              Roche master mix 2X                                        
0.4µl                           Fwd primer (10um)                                            
0.4µl                           Rev primer (10um)                                             
2.1µl                           ddH2O                                                                     
0.1µl                           Probe                       
                                             
The PCR reaction was carried out with an ABI 7900HT (Applied Biosciences) 
instrument using the following conditions: 50°C 2min, 95°C 10min, 40 cycles of 
95°C 15 seconds and 60°C 1min, lastly 60°C 1min.  
  
Western blot  
 ~ 5 x 106  lymph cells were used to prepare the western blot sample. Cells were 
washed once with PBS, and then lysed in 100µl RIPA buffer supplemented with 10% 
protease inhibitor cocktail on ice for 30min. The lysates were centrifuged at 
14000rpm for 15min to remove cell debris. The supernatant was transferred into new 
eppendorf tubes. The protein concentration was measured with BCA protein assay kit 
(Novagen). 
 
Western blot was done with BioRad Protean 3 system. Before loading samples into 
gel, the same amount of proteins was mixed with Laemmli buffer and boiled at 95°C 
for 10 minutes. Samples and protein ladders were run on a 12 % acrylamide gel. Once 
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protein ladder reached the bottom of the gel, samples were transferred onto a nylon 
membrane at 100V for 90min. After transfer, the membrane was blocked with a 5% 
fat-free milk solution for 1 hour at room temperature. The primary antibody was then 
added at 4°C overnight (anti-PEP: 1:1000; anti actin: 1:1000; anti-tetR: 1:1000). The 
following day, the membrane was washed with 0.2% TBST buffer 3 times for 20 
minutes to remove excess antibody. The secondary antibody was diluted and 
incubated with membrane at room temperature for 1 hour, then washed with 0.2% 
TBST solution. The membrane was incubated in ECL reagent (PerkinElmer) for 1 
minute. The membrane was then exposed to a camera to capture an image (Fluor 
Chem Q, Alpha Innotech). 
 
2.2.11 Cell purification  
Single cell suspensions were prepared from pooled peripheral lymph nodes and spleen 
for isolation of cell subpopulations. All the isolations were done with Miltenyi cell 
isolation kits according to the manufacturer’s instructions. CD4+ cells were purified 
using negative selection by removing magnetic bead bound CD8, B cells, DC, 
Macrophages, NK, NKT cells. CD25 is selectively highly expressed on Treg cells. To 
isolate Treg (CD4+CD25+) cells, CD4+ cells were incubated with PE-conjugated anti-
CD25 mAb and then anti-PE microbeads. To purify CD4 naïve and effector cells 
(CD62Lhi and CD62Llo, respectively), CD4+ cells were incubated with anti-CD62L 
beads, washed in the magnetic separator. CD4 effectors flowed through, while CD4 
naïve T cells are retained in the column. For isolation of B cells, splenocytes were 
incubated with anti-CD19 or anti-CD43 microbeads by positive and negative 
isolation, respectively. Peritoneal exudates cells (PEC) were obtained by washing 
peritoneal cavity with PBS 1% FCS. PEC were incubated with anti-CD11b 
microbeads to purify PEC macrophages. Splenocytes were incubated with anti-CD11c 
microbeads to isolate dentritic cells (DC). 
 
2.2.12 Cell differentiation 
Depending on reaction conditions, naïve CD4 T cells can differentiate into Th1, Th2, 
Th17 and Treg cells in vitro. In this project, we tested the capacity of naïve T cells to 
differentiate into Treg cells. 2µg anti-CD3 was coated on a 24-well plate at 37°C for 
3-4 hours. Unbound anti-CD3 was washed away with PBS. 0.4-0.5 x 106  naïve CD4 
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T cells were cocultured with 2µg/ml anti-CD28 and 0.5ng/ml TGF-β. 1µg/ml Dox was 
added when cells were prepared from Dox treated mice. After 3 days incubation, the 
frequency of Foxp3+ cells was analyzed by intracellular Foxp3 staining. 
 
2.2.13 Proliferation assay 
Proliferation assays are determined by [3H]-thymidine incorporation. When cells were 
prepared from Dox treated mice, 1µg/ml Dox was added to the culture medium. 
Proliferation of T cell subpopulations and thymocytes was performed by incubation 
with anti-CD3/CD28 Dynalbeads or PMA and ionomycin in 96-well plates. To test 
proliferation of Treg cells, Treg cells were cocultured with anti-CD3/28 Dynalbeads, 
or dendritic cells (along with 1µg/ml anti-CD3) in RMPI medium supplemented with 
2000IU IL-2. To check the long-term expansion capacity of Treg cells, purified Treg 
cells were cocultured with anti-CD3/28 Dynalbeads, DC or PEC macrophages 
supplemented with IL-2. Every 2-3 days, half of the medium was carefully replaced 
with fresh medium. Cells were pulsed with 25µl [3H]-thymidine (0.5 µCi/well) 16 
hours before harvesting.  
       
2.2.14 Suppression assay  
A suppression assay was used to test Treg cell suppressive function in vitro. Purified  
wild type conventional T cells (CD4+CD25-, 2.5 x 104) were cocultured with different 
numbers of Treg cells along with irradiated (20 Gy) splenocytes (2.5 x 105). 1µg/ml 
anti-CD3 is added into wells to stimulate conventional T cell proliferation for 3 days. 
Cells are pulsed with 25µl [3H]-thymidine (0.5 µCi/well) 16 hours before harvesting.  
 
2.2.15 B cell activation and proliferation 
B cells were purified from splenocytes using anti-CD19 or anti-CD43 microbeads 
(Miltenyi). 1x105 purified B cells were stimulated with LPS, serially diluted anti-IgM 
F(ab)’2 or anti-CD40. 1 day after stimulation, cells were stained with PE-Cy7 
conjugated anti-CD69 and APC conjugated anti-CD25 to measure B cell activation. 2 
day after stimulation, cells are pulsed with 25µl [3H]-thymidine (0.5 µCi/well) 16 
hours before harvesting to test for proliferative capacity. 
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2.2.16 PLC-γ2 phosphorylation during B cell activation 
Mice were first treated with Dox for 1 month. Wild type and transgenic (GFP+) B 
cells were mixed at 1:1 ratio, and then stained with pacific blue conjugated anti-CD19 
mAb. Cells were resuspened in RPMI medium at 20 x 106/ml. Cells were warmed to 
37°C for at least 10min. 25µl (0.5 x 106 ) cells were aliquoted into a 96-well plate, and 
then activated with 40µg/ml anti-IgM F(ab)’2 for 1, 3, 5, 10 min. Cells were 
immediately fixed with 150µl FixΙ (BD) at 37°C for 10min, then washed, and 
permeabilized with Perm ΙΙΙ buffer (BD) on ice for 15min.  Cells were washed with 
PBS 1%FCS, stained with PE-conjugated anti-PLC-γ2 mAb (pY759, 1:200 diluted) at 
4°C for 30min. Cells were then washed again and analyzed by flow cytometry. 
 
2.2.17 Flow cytometry  
Flow cytometry utilizes fluorophore conjugated mAbs to simultaneously measure 
multiple protein expression levels within single cells. For cell surface staining, -5x105 
cells in suspension were first incubated with CD16/32 mAb at 4°C for 10 min to 
reduce unspecific antibody binding. The mixture of desired antibodies was added to 
cells at 4°C for 30min. Cells were washed twice with PBS 1%FCS, and then analyzed 
by flow cytometry. 
 
To detect intracellular protein expression levels, surface staining was first employed 
to identify extracellular markers. Cells were then fixed and permeabilized to allow 
antibody to access intracellular tissues. FoxP3 staining was performed using a FoxP3 
staining kit (eBioscience) according to manufacturer’s instruction.  
 
For FACS analysis of cell apoptosis, cells were stained with 7-AAD and a Annexin V 
mAb. Annexin V recognize phosphatidylserine (PS) which is predominantly located 
in the inner leaflet of plasma membrane in live cells. During the early stage of 
apoptosis, PS moves to the extracellular membrane, which makes it detectable by 
Annexin V. Cell membrane is still intact to exclude viability dye 7-AAD. In the late 
stage of apoptosis, integrity of the cell membrane is compromised and unable to 
exclude 7-AAD. To analyze cell apoptosis, cells were first surface stained, washed 
and incubated with 50µl (diluted 1:50) 7-AAD at 4°C for 15min. Cells were washed 
again and analyzed by FACS. 
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2.2.18 anti-CD3 stimulation in vivo  
To test T cell activation and proliferation in vivo, 10µg anti-CD3 was injected i.v.  
into 10 day Dox-treated wt and transgenic mice. 2 days later, mice were dissected to 
obtain peripheral lymph nodes and spleen. Lymph node cells and splenocytes were 
stained with anti-CD4, CD8, TCR, Ki-67, CD62L and CD44 mAbs to analyze the 
proportion of effector T cells and dividing cells.  
 
2.2.19 Cytokine production by ELISA and CBA kit  
 Purified naïve and effector T cells were stimulated with anti-CD3/28 dynalbeads 
(Invitrogen) for 3 days. On day 4, 60µl supernatant was taken out from each well to 
measure IL-2, IL-17, IL-4, IL-10 and IFN-γ production using CBA kit (BD) and 
ELISA assay (eBioscience). The assays are carried out according to manufacturer’s 
instructions.  
 
2.2.20 Colitis induction 
Mice homozygous for the SCID mutation lacks functional T and B cells. Thus, 
NOD.scid mice provide a lymphopenic environment allowing for expansion of 
exogenous cell populations. CD4+CD45RBhi cells are purified and then transferred 
into NOD.scid mice to induce colitis. Briefly, CD4+ T cells were isolated according to 
manufacturer’s manual (Miltenyi). CD4+ cells were incubated with biotinylated anti-
CD45RB mAb (1:800) and CD16/32 at 4°C for 5min. Cells were washed twice and 
then incubated with anti-biotin microbeads. Cells retained in magnetic separator were 
CD4+CD45RBhi cells. 0.5-1x106 cells are injected i.v. into NOD.scid mice. After 6-7 
weeks, mice were dissected. The colon was cut into five pieces, fixed in 4% PFA at 
4°C overnight. The colon tissues were then embedded in paraffin, cut and stained with 
H&E. The inflammation in colon was scored under microscope by Dr. Alma 
Zernecke. 
 
2.2.21 Diabetes test 
NOD mouse develops diabetes spontaneously. In some cases, diabetes was induced 
by adoptive transfer or Treg cell depletion. In this project, diabetes incidence was 
tested by the following three approaches: 
Spontaneous diabetes: Nine groups of female NOD mice were used to test 
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spontaneous diabetes incidence: untreated WT, P2, P4, and WT, P2, P4 treated with 
Dox from 4 or 10 weeks old. Mice were tested for diabetes once a week using Diastix 
(Bayer). When mice were tested hyperglycemic in two consecutive tests, they were 
considered diabetic. 
 
Cyclophosphamide (CY) induced diabetes: Cyclophosphamide can induce diabetes 
by depleting Treg and B cells. Male mice were treated with Dox for at least 1 month. 
Cyclophosphamide was prepared at 20 mg/ml in PBS. Mice were first weighed, and 
injected i.p. with 200µg CY/g body weight. Mice were tested for diabetes every 2 
days with Diastix (Bayer). 
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The gene PTPN22 is widely associated with many human autoimmune diseases, 
including T1D (Bottini et al., 2004; Smyth et al., 2004; Ladner et al., 2005; Onengut- 
Gumuscu et al., 2004). The disease susceptibility is conferred by the SNP (C1858T), 
causing the substitution from arginine to tryptophan (R620W) (Bottini et al., 2004). 
Further studies have identified R620W in Lyp is a gain-of-function mutation, 
illustrated by the reduced responsiveness of T and B cells when carrying 
heterozygous PTPN22 allele (Vang et al., 2005; Rieck et al., 2007; Aarnisalo et al., 
2008;). In B6 mice, the corresponding mutation in Ptpn22 (Pep) is R619W. A recent 
paper reported the generation of a R619W knockin mouse. This transgenic mouse 
showed a similar phenotype to the Pep knockout mouse. Further experiments showed 
that this mutation accelerated Pep degradation, indicating that Pep-619W was a loss-
of-function variant (Zhang et al., 2011). The controversial conclusions on the 
mutation in Lyp/Pep increase the difficulty of understanding the role of Lyp/Pep in 
autoimmune diseases. The aim of this project was to utilize inducible RNAi to 
explore the role of Pep in the pathogenesis of autoimmune diseases, especially in type 
1 diabetes (T1D) and colitis. The reason for choosing these two autoimmune diseases 
is that Pep reversely modulates T1D and colitis (Vang et al., 2005; Frank et al., 2011; 
Rivas et al., 2011; Diaz-Gallo et al., 2011). If Lyp-620W is a gain-of-function variant, 
Ptpn22 silencing should prevent or delay diabetes and exacerbate colitis in the 
inducible knockdown (KD) mice; if the opposite is true, Ptpn22 silencing should 
accelerate diabetes and reduce the severity of colitis.    
 
In this project, inducible RNAi is utilized to functionally study of Ptpn22 in 
autoimmune diabetes and colitis. Backcrossing knockout B6 mice into the NOD 
background may introduce B6 genome fragments in addition to the  Ptpn22 KO allele, 
that can interfere with the interpretation of Pep’s function in the NOD mouse. 
Compared to the KO technique, inducible RNAi has several advantages. 
Hypomorphic function and reduced expression of proteins are more common in vivo. 
RNAi provides a better mimick of the physiological states than complete loss of 
protein. Moreover, RNAi is a powerful tool to study the role of specific splice isoform 
(Gerold et al., 2011; Pecot et al., 2011; Kim et al., 2007). Since Pep is also involved 
in thymocyte selection and maturation, inducible knockdown, which can silence 
Ptpn22 from 5-7 weeks of age when most thymocytes have already matured, can be 
used to mimick drug treatment in human patients.  
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Briefly, shRNAs were first designed, screened and cloned into the inducible shRNA 
expression vector. This vector was packaged into the lentivirus to generate lentiviral 
transgenic founders. The founders were then mated with WT NOD mice to separate 
the multiple copies of the integrated lentiviral transgene. To identify artifacts due to 
off-target effects of RNAi, in this project, two transgenic NOD mouse lines, which 
carried inducible P2 and P4 shRNA respectively, were generated, established and 
characterized.  
 
3.1 shRNA design and validation 
In this project, inducible RNAi was employed to study the role of Pep in the NOD 
mouse. In RNAi, there are two types of small RNAs, endogenous micro RNAs 
(miRNAs) and small interfering RNAs (siRNAs). The primary miRNAs usually come 
from the processing of long RNA transcripts. The primary miRNAs are cleaved by 
Drosha to remove the hairpin, followed by Dicer to remove loop and cut the miRNA 
into a mature miRNA of 21-23 base pairs. In the case of siRNAs, long double strand 
RNAs are cleaved into 21-23 base pairs by Dicer. The 21-23 base pairs are then 
unwound and disassociated. The anti-sense strand is loaded into RNA induced 
silencing complex (RISC). The perfect matching between anti-sense strand and 
complementary sequences in the target mRNAs results in the target mRNAs 
degradation. Imperfect matching leads to repression of mRNA translation and 
subsequent protein reduction. 
 
To efficiently silence Ptpn22, 8 different shRNAs were designed by Dr. Stephan 
Kissler. These shRNA oligos were phosphorylated, annealed and then cloned into the 
pLB vector, in which shRNA was constitutively expressed from the CMV promoter. 
The shRNA knockdown efficiencies were tested by luciferase reporter assay.  
 
In the luciferase reporter assay, 293 F cells were co-transfected with pLB and psi-
check2 vector. In the psi-check2 vector, firefly luciferase is constitutively expressed 
and used to normalize results to account for variable  transfection efficiency. Ptpn22 
cDNA was inserted behind renilla luciferase mRNA, into the 3’ UTR. If shRNA 
works efficiently, the fusion mRNA will be degraded, resulting in the reduction of 
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renilla luciferase signal. Thus, the reduction of renilla luciferase should be an 
indicator of shRNA knockdown efficiency.  Our results showed that shRNA P2 and 
P4 possessed the highest knockdown efficiencies, which were selected and inserted 
into the inducible shRNA expression vector (Fig 3.1). 
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Fig 3.1 Validation of 8 Ptpn22 shRNA knockdown efficiencies by luciferase reporter assay.  Assay 
was done in duplicates against Ptpn22 cDNA.   
 
3.2 Generation and validation of inducible shRNA expression vector  
The inducible shRNA expression vector FH1t-UTG was kindly provided by Dr. MJ 
Herold. By using an inducible shRNA expression vector, we can start the gene 
silencing at any time, just by adding Doxycycline (Dox) into the culture medium or 
the mouse’s drinking water. Moreover, we can study phenotype recovery or duration 
after removing Dox from drinking water. 
 
The basis for inducible RNAi is a tetracycline operator-repressor controlled promoter 
driving shRNA expression. In this dual promoter vector, shRNA is transcribed by the 
polymerase ΙΙΙ H1 promoter containing tetracycline operator (TetO), and ubiquitin 
promoter constitutively expresses tetracycline repressor (TetR) and GFP. TetR blocks 
shRNA expression by binding to TetO. By adding Dox into mouse drinking water or 
food, TetR is removed and degraded. Thus, shRNA is allowed to be transcribed and to 
silence Ptpn22 (Herold et al., 2008). 
 
Luciferase reporter assays using the pLB backbone demonstrated that shRNAs P2 and 
P4 displayed the highest knockdown efficiencies. The next step was to clone these 
two shRNA sequences into the FH1t-UTG vector. shRNAs were synthesized, 
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annealed and first cloned into the pH1tet-flex vector. The fragment containing the H1 
promoter and TetO was cleaved and inserted into the final vector, FH1t-UTG. The 
vectors were sequenced using the FUW1 primer to make sure the shRNA sequences 
were correct. 
 
We again used a luciferase reporter assay to validate the inducible shRNA expression 
constructs. 293F cells were co-transfected with psi-check 2 and inducible shRNA 
vectors. 3µg/ml Dox was added to induce shRNA expression. However, in the 
absence of Dox, P2 and P4 shRNA still induced reporter knockdown. We reasoned it 
could be that shRNA had time to accumulate prior to expression of the TetR which 
subsequently represses shRNA transcription in the absence of Dox. To overcome this 
challenge, we first used the inducible shRNA expression vectors to generate a small 
amount of lentivirus, which we then used to infect 293 F cells in 6-well plates. The 
transduced cells were transfected with psi-check 2 vector with or without Dox. The 
renilla signal in no Dox cells was set to 100%. In the presence of Dox, P2 and P4 
shRNAs showed high knockdown efficiencies similar to results obtained with the 
pLB vectors (Fig 3.2).  
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Fig 3.2 Validation of inducible P2 and P4 shRNA expression vectors by luciferase reporter assay.  293 
F cells were first infected with lentivirus, and then transfected with psi-check 2 vector with or without 
Dox. Assay was done in duplicates.   
 
3.3 Lentivirus generation and titration 
Lentivirus, which is derived from HIV-1immunodeficiency virus, can efficiently 
incorporate its genetic material into genomic DNA in both dividing and non-dividing 
cells. Lentivirus provides a valuable research tool for studying gene function in vivo.  
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To generate lentivirus, 8-9 x 106  293 F cells were co-transfected with 3µg pCMV-
VSVg, 3µg RSV-rev, 4µg pMDL-gag/pol, 5µg pAdvantage, 20µg inducible shRNA 
construct along with 70µl Fugene HD. 48 hours later, supernatant was collected, spun 
down and filtered. Lentivirus was then ultracentrifuged at 25000rpm for 90min. The 
Lentivirus was recovered in PBS at 4°C overnight. The next day virus was carefully 
aliquoted, flash-frozen in liquid nitrogen and stored at -80°C.  
 
To titrate lentivirus, 0.01, 0.1, and 1µl lentivirus were used to infect 293 F cells. 24 
hours later, cells were washed and run through flow cytometry to measure the 
percentage of GFP+ cells. To calculate virus titer, we assumed that after 24h growth, 
293 F cells had doubled in numbers to around 8 x105. The lentivirus titer was 
estimated as cell number x frequency of GFP+ x 1000/ml. Hence, the titers of P2 and 
P4 lentiviruses were calculated as 3x 108 and 4x 108, respectively, which could be 
used to generate inducible transgenic NOD mice (Fig 3.3).  
0 10 2 10 3 104 105
GFP
0
10
2
10 3
10
4
10
5
PE
0.024
0 10 2 10 3 104 105
GFP
0
10
2
10 3
10
4
10
5
PE
0.024
0 10 2 10 3 104 105
GFP
0
10
2
10 3
10
4
10
5
PE
37.4
0 10 2 10 3 104 105
GFP
0
10
2
10 3
10
4
10
5
PE
50
P2
P4
no virus 1ul virus
  
Fig 3.3 Lentivirus titration. 293 F cells were infected with 0.01, 0.1, and 1µl lentivirus to determine the 
virus titration. The frequencies of GFP+ in cells with no virus and 1µl virus were shown. GFP+ 
frequencies in cells with 0.01 and 0.1µl viruses were in accordance with virus dilution. 
 
3.4 Generation of transgenic P2 and P4 mouse lines 
To generate lentiviral transgenic mice, single cell NOD embryos were microinjected 
with lentivirus. Female mice were injected with PMS, followed with hCG to induce 
ovum. After an overnight mating with males, females were euthanised and oviducts 
were dissected to collect single cell embryos. Lentivirus was injected into the 
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perivitelline space of embryos. Infected embryos were implanted into the uterus of 
pseudopregnant females to deliver transgenic pups. To control for possible off-target 
effects of RNAi, two transgenic mouse lines (P2 and P4), which carried P2 and P4 
shRNAs respectively, were generated. The assumption was if similar phenotypes 
could be found in both P2 and P4 knockdown mice, our conclusion would be more 
convincing. 
 
In the shRNA expression cassette, GFP was constitutively expressed by the ubiquitin 
promoter. Thus, GFP was a reliable marker for transgenic mice. Blood samples were 
collected to measure GFP expression. GFP positive founders were mated with WT 
NOD mice to segregate the multiple copies of the integrated lentiviral transgene. The 
number of functional transgene copies was determined by GFP+ proportion in the 
offspring as well as peak numbers in GFP histogram. After breeding transgenic lines 
for 4 generations, the frequency of GFP+ pups went down to ~50%, and single peak of 
GFP histogram could be observed in blood lymphocytes. All these data demonstrated 
that only one functional copy of the transgene was present in the P2 and P4 mouse 
lines. The lines were then expanded for inducible knockdown validation, diabetes test 
and functional studies. 
 
Fig 3.4 GFP expression in the blood lymph cells of established P2 and P4 mouse lines. Blood cells 
were treated with ACK buffer, washed and analyzed by flow cytometry. WT (open histogram) showed 
an negative control for GFP. P2 and P4 were showed in grey histogram. 
 
3.5 Inducible knockdown validation 
Next we validated that P2 and P4 shRNAs could silence Ptpn22 in vivo. To confirm 
that knockdown could be modulated in an inducible manner, six groups of mice were 
used: WT, P2, and P4 mice either treated with 200 µg/ml Dox for 7-10 days or left 
untreated. Untreated P2 and P4 mice were used to examine if shRNA expression was 
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leaky in the absence of Dox. Some WT mice were also treated with Dox to examine 
the effect of Dox in non-transgenic mice. 7-10 days later, mice were dissected to 
obtain lymph nodes. Lymph nodes were disaggregated and prepared for qRT-PCR 
and western blot. 
 
qRT-PCR was carried out with Taqman probe and universal probe master mix (ROX). 
ROX, a passive reference dye, can compensate variations between wells to improve 
the precision of the results. Taqman probe consists of a quencher dye at the 3’ end and 
a reporter dye at the 5’ end that was quenched before PCR reaction. During the PCR 
reaction, the Taqman probe is cleaved by DNA polymerase, resulting in a 
corresponding increase of reporter dye intensity. The housekeeping gene GAPDH was 
used to normalize samples to amplification efficiency. The cycle threshold (Ct) values 
of GAPDH and Ptpn22 were determined by the PCR program automatically.  The 
abundance of Ptpn22 in each group was calculated by Δ CT value (Ptpn22 Ct value – 
GAPDH Ct value). To compare Ptpn22 abundance in control mice (untreated WT, P2, 
P4 and Dox-treated WT) and Dox-treated P2, P4 mice, we calculated ΔΔCT value (Δ 
Ct value – WT Δ Ct value). The result showed that ΔΔCT values were comparable in 
untreated WT, P2, P4 and Dox-treated WT cells. The ΔΔCT values were increased by 
1-2 cycles, indicating a 50-75% reduction of Ptpn22 mRNA in Dox-treated P2 and P4 
cells (Fig 3.5). These results confirmed that in the P2 and P4 mice, RNAi could be 
achieved on the mRNA level in an inducible manner. Moreover, Dox did not 
influence Ptpn22 mRNA transcription and stability.  
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Fig 3.5 Validation of inducible RNAi by qRT-PCR. The abundance of Ptpn22 in each group was 
calculated by ΔCT value (Ptpn22 Ct value – GAPDH Ct value). ΔΔCT values (ΔCt value – WT ΔCt 
value) were used to compare Ptpn22 abundance in control mice (untreated WT, P2, P4 and Dox-treated 
WT) and Dox-treated P2 and P4 mice. 
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We also validated inducible Pep knockdown by western blot. Lymph node cells were 
lysed in RIPA buffer (containing proteinease inhibitor cocktail) in ice for 30min. The 
lysates were spun down, and then incubated with BCA solution (Novagen) to measure 
protein concentrations. Proteins were separated and blotted with antibodies to detect 
actin, Pep and TetR.  Similar to the the result in qRT-PCR, Pep levels were 
comparable in untreated WT and P2 mice, as well as in Dox treated WT mice. The 
reduction of Pep was only observed in the Dox-treated P2 mice. The strong bands of 
TetR confirmed P2 were lentiviral transgenic mice (Fig 3.6A). Along with qRT-PCR 
data, we confirm in our KD mice, Ptpn22 can be inducibly silenced. Next P2 and P4 
mice were treated with a serial concentration of Dox to compare knockdown 
efficiencies in P2 and P4 mice. With the increase of Dox in the drinking water, loss of 
Pep reached to ~80% of loss with 2 µg/ml Dox in P2 mice. A less knockdown 
efficiency in P4 mice could be observed (~60% of loss). The increase of Dox (from 2 
µg/ml for P2, and from 20 µg/ml for P4) did not improve knockdown efficacy any 
more (Fig 3.6B). Dox will gradually degrade in the water. Unlike changing drinking 
water 3 times a week as Herold and colleagues did, in this project Dox is regularly 
added into mouse drinking water on every Monday without change. To maintain the 
maximal knockdown efficiency during the whole week, 200 µg/ml Dox is used in the 
treatment of mice in the subsequent experiments. The following studies showed that 
there are no differences between untreated WT and Dox-treated WT mice, indicating 
200 µg/ml Dox does not exert any side effect on the NOD mouse.  
A. B.
 
Fig 3.6 Validation of inducible RNAi by western blot. A. Western blot figure. Proteins were blotted 
with anti-actin, Pep and TetR antibodies to detect protein expression levels. B. Pep protein levels from 
KD mice treated with a serial concentration of Dox were quantified with Image J.  
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3.6 Prolonged Pep knockdown increases spleen cellularity 
In the mouse, Ptpn22 encodes a tyrosine phosphatase, Pep. The substrates of Pep have 
been identified, including Lck, Fyn and ZAP-70. Pep can attenuate TCR/BCR 
signaling by dephosphorylating the positive regulatory tyrosine phosphorylation in 
Lck, Fyn and ZAP-70. Thus, Pep is a negative regulator in T/B cell activation. 
Correspondingly, splenomegaly and lymphadenopathy occured in old, but not young 
Pep knockout and knockin B6 mice. Since Ptpn22 silencing is detectable after 7-10 
day Dox treatment, an interesting question was if we could see similar phenotype in 
our inducible knockdown mice.  
 
To make sure the phenotype was due to the inducible knockdown, we usually utilized  
six groups of mice: untreated and 200µg/ml Dox treated WT, P2 and P4 mice. The 
mice were treated with Dox from 5-7 weeks of age for a duration of 4-5 months. The 
lymph nodes and spleen were then dissected to count cell numbers. The results 
showed that cell numbers in the lymph nodes were quite similar (data not shown). 
Similar to the Ptpn22 KO and knockin mice, cellularities were significantly increased 
in the spleen of Dox-treated P2 and P4 mice. Moreover, in agreement with the higher 
KD efficiency in the Dox-treated P2 mice, more splenocytes could be found in the P2 
KD than P4 KD mice (Fig 3.7). The similarities of increased spleen cellularity in KO, 
knockin and inducible KD mice strongly suggested that P2 and P4 mice were reliable 
models to explore the function of Pep in the NOD mouse.  
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Fig 3.7 Prolonged Ptpn22 silencing increased spleen cellularity. Mice were treated with Dox for 4-5 
months, and then dissected to count cell numbers (*: P<0.05; **: P<0.01) 
 
3.7 The effect of inducible Ptpn22 silencing on T cell subsets 
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Since we saw that long-term Ptpn22 silencing boosted the number of splenocytes, we 
next analyzed which cell populations were influenced. Considering Ptpn22 was 
predominantly expressed in T and B cells, we first examined the role of Ptpn22 
silencing on T cell subsets. 
 
T cells are matured in the thymus. During T cell development, positive selection and 
negative selections occur to protect the body from infection as well as to avoid self-
tissue destruction. Double-positive immature thymocytes obtain the survival signal 
when reacting to self-antigen presented on thymic stromal cells. Surviving 
thymocytes undergo negative selection to deplete autoreactive T cells with high 
affinity to self-antigen. Mature T cells then upregulate CD62L and CCR7 to facilitate 
migration into secondary lymphoid organs. Once these T cells encounter antigen in 
the periphery, CD62L is down-regulated to slow down migration. T cells are then 
activated, converted into effector/memory T cells, followed with proliferation and 
secretion of cytokines.  Another T cell subpopulation, regulatory T cell (Treg) cells, 
plays a vital role in the self-tolerance. In this project, we systematically examined the 
effect of inducible Ptpn22 silencing on T cell development and on the function of T 
cell subsets. 
 
3.7.1 Inducible Ptpn22 silencing does not influence thymocyte development 
Several papers reported that Lyp/Pep participates in T cell development. Hasegawa et 
al demonstrated that in the absence of Pep, positive selection in thymus was enhanced 
in the context of TCR transgene while negative selection was not affected (Hasegawa 
et al., 2004). CD5 expression was enhanced in the double positive (DP) thymocytes, 
indicating elevated TCR signaling in DP thymocytes (Hasegawa et al., 2004; Azzam 
et al., 1998). Thymocytes from Ptpn22 knockin mice were hyperproliferative in 
response to anti-CD3/CD28 stimulation (Zhang et al., 2011). In this project, Ptpn22 
was silenced from 5-7 weeks of age, when most thymocytes have already matured 
(Scollay et al., 1980). In this scenario, thymocyte development should not be altered 
in our inducible P2 and P4 KD mice.   
 
To test this hypothesis, WT, P2 and P4 mice were treated with Dox from 5-7 weeks of 
age for 1 month. Some mice were left untreated as a control. Thymocytes were then 
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obtained and stained with fluorophore-conjugated anti-CD4, CD8 and CD5 mAbs. 
The results showed that the frequencies of CD4 single positive, CD8 single positive 
and DP cells were similar in control (WT, P2, P4, and Dox-treated WT) and P2, P4 
inducible KD mice. Furthermore, CD5 expression in DP thymocytes was not altered, 
indicating that TCR signaling was not affected in DP thymocytes (Fig 3.8).  
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Fig 3.8 Inducible Ptpn22 silencing didn’t alter T cell development. A. The distribution of single CD4, 
CD8 and DP thymocytes. B. CD5 expression in DP cells.  
 
In Ptpn22 knockin mice, thymocytes were hyperresponsive to anti-CD3/CD28 
stimulation (Zhang et al., 2011). Although cell staining in thymocytes did not show 
any discrepancies, we also tested the proliferative capacity of thymocytes after 1 
month of Pep silencing. Thymocytes were stimulated with anti-CD3/CD28 dynabeads 
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(Invitrogen) at different bead:cell ratios. Cell proliferation was measured by the 
uptake of [3H]-thymidine. We found comparable cell proliferation in control and Pep 
KD thymocytes (Fig 3.9). The unaltered cell distribution and CD5 expression in DP 
thymocytes suggests that inducible Ptpn22 silencing from 5-7 weeks of age does not 
alter thymocytes development and proliferation.  
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Fig 3.9 Proliferation of thymocytes were comparable. Thymocytes from control and inducible KD mice 
were stimulated with different numbers of anti-CD3/CD28 dynalbeads for 3 days. Proliferation was 
measured by the incorporation of [3H]-thymidine.  
 
3.7.2 The effect of inducible Ptpn22 silencing on non-Treg T cells 
 
3.7.2.1 Ptpn22 silencing in adult mice does not boost effector T cells 
When thymocytes mature, CD62L expression is upregulated to faciliate naïve T cells 
migrating into peripheral lymphoid organs. When naïve T cells encounter antigen and 
differentiate into effector/memory T cells in the periphery, CD62L is downregulated 
and CD44 expression is enhanced. Thus, effector/memory T cells are determined as 
CD44hiCD62Llo. Correspondingly, naïve T cells are marked as CD44loCD62Lhi. 
 
Lyp/Pep negatively modulates T cell activation and the generation of 
effector/memory T cells. In vitro, PTPN22 knockdown increased antigen-receptor 
signaling in Jurkat T-cell line, while overexpression suppressed T cell activation 
(Begovich et al., 2004; Cloutier et al., 1999). In the Ptpn22 knockout and knockin 
mouse, effector/memory T cell pool was expanded, especially in the older mice 
(Hasegawa et al., 2004; Zhang et al., 2011).  
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To examine the role of Ptpn22 silencing on effector/memory pool in our inducible 
knockdown mice, mice were treated from 5-7 weeks of age for 1month. Lymph nodes 
and spleen were obtained and prepared for FACS staining. To determine naïve, 
effector/memory and Treg cells in a single panel, cells were stained with fluorophore-
conjugated anti-CD4, CD8, CD25, TCR, CD62L, CD44 and subsequently 
permeabilized and stained with anti-Foxp3 mAb. Cells were first gated with 
CD4+TCR+ to identify CD4+ T cells. In CD4+ T cells, Treg cell were gated as Foxp3+, 
effector/memory T cells were determined as CD62LloFoxp3-, and naïve T cells were 
identified as CD62LhiFoxp3-.  We found proportions of effector/memory T cells were 
similar in each group, indicating that 1 month of Pep KD does not expand the 
effector/memory T cell pool (Fig 3.10A). We hypothesized that this could be due to 
the short duration of gene silencing, as the accumulation of effector/memory T cells 
was only observed in older KO mice. We therefore explored if effector/memory T 
cells would accumulate after a longer period of gene silencing. P2 and P4 mice were 
treated with Dox for 8 months. Similar to the results in 1-month treated mice, the 
effector/memory T cell pool was not affected in the lymph node compartment, and 
slightly increased in the splenic CD4+ T cell compartment of P2 inducible KD mice 
(Fig 3.10B). Our data showed that if mice were treated with Dox from 5-7 weeks of 
age, Ptpn22 silencing did not significantly boost the effector/memory T cell pool in 
either P2 or P4 inducible KD mice, which was distinct to Ptpn22 KO and knockin 
mice.  
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Fig 3.10 Retained effector/memory T cell pool in adult KD NOD mice. A. Mice were treated with Dox 
from 5-7 weeks old for 1month. B. Mice were treated with Dox for 8months. The proportion of 
effector/memory CD4+ T cells in the LN and SP were shown. No significant differences could be 
observed. 
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3.7.2.2 Ptpn22 silencing facilitates Teff T cell generation   
 
We have shown that under homeostatic condition, Ptpn22 silencing could not boost 
effector/memory pool, even in long-term treated mice. But we had not investigated 
the effect of Ptpn22 silencing during T cell priming conditions. For this purpose, we 
decided to stimulate T cells in vivo. We used anti-CD3, a potent stimulator for all the 
T cells. 10µg anti-CD3 or PBS alone was injected i.v. into 10-day Dox treated WT 
and P4 mice. Two days later, mice were dissected to obtain lymph nodes and spleen. 
Cells were surface stained to check the effector/memory T cell pool in T cells, and 
then pemeabilized, stained with anti Ki-67 mAb to identify dividing cells. We found 
Ptpn22 silencing facilitated effector/memory T cell generation under anti-CD3 
priming (Fig 3.11). It seemed that under homeostatic condition, Ptpn22 silencing may 
enhance TCR signaling, but not sufficiently to generate more effector/memory T 
cells. When Ptpn22 KD T cells encountered antigen, they were converted into 
effector/memory T cells more efficiently.  
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Fig 3.11 Inducible Ptpn22 silencing facilitated effector/memory T cell generation under the priming 
condition. Mice were treated with Dox for 10 days to knockdown Pep, and then injected with anti-CD3 
or PBS. The frequencies of effector/memory T cells in CD4 (A) and CD8 (B) T cells were shown. 
 
3.7.2.3 Ptpn22 silencing from birth boosts effector/memory T cell pool 
In most experiments, Ptpn22 silencing started from 5-7 weeks of age when most 
thymocytes have been matured (Scollay et al., 1980). In the KO and knockin mice, 
Pep has been confirmed to be involved in thymocyte education (Hasegawa et al., 
2004; Zhang et al., 2011).  We then asked if the expanded effector/memory T cells 
were related to the role of Pep in the thymic education. To test this hypothesis, WT, 
P2 and P4 mice were treated with Dox from birth for 2month. Surprisingly, similar to 
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Ptpn22 KO and knockin mice, effector/memory T cells were significantly increased 
in the spleen and to a lesser extent in the P2 inducible KD lymph nodes, indicating 
Pep may determine peripheral effector/memory T cell pool through thymocyte 
education (Fig 3.12).  
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Fig 3.12 The expanded splenic effector/memory T cell pool when P2 and P4 mice were treated with 
Dox from birth for 2 months. (*: P<0.05) 
 
3.7.2.4 Ptpn22 silencing does not alter T cell proliferation  
 
Lyp/Pep acts as an important negative regulator in TCR signaling. Hasegawa and 
collegues assayed the proliferation of naïve and effector/memory T cells from Ptpn22 
deficient mice. They found that loss of Pep only enhanced effector/memory T cell 
proliferation, but not that of naïve T cells (Hasegawa et al., 2004). In this project, we 
examined the proliferation of naïve and effector/memory T cells by different 
approaches. 
 
In vitro, we assayed the proliferation of Ptpn22 KD T cells in response to TCR 
stimulation. Effector and naïve CD4+ T cells were isolated from 1 month Dox-treated 
mice using magnetic microbeads (Miltenyi) according to manufacturer’s instructions. 
Naïve or effector CD4+ T cells were stimulated by different numbers of anti-
CD3/CD28 dynabeads (invitrogen). To continuously silence Pep, 1µg/ml Dox was 
added when cells were purified from Dox-treated mice. Cell proliferation was assayed 
by the uptake of [3H]-thymidine. We found compared to control  (WT, P2, P4 and 
Dox-treated WT) cells, KD naïve and effector T cells showed similar proliferation 
capacities, indicating Ptpn22 silencing after thymocytes education didn’t alter T cell 
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proliferation (Fig 3.14).  
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Fig 3.14 Naïve and effector/memory CD4+ T cell proliferation. Mice were treated with Dox for 1 
month. naïve (A) and effector/memory (B) T cells were isolated and stimulated with anti-CD3/CD28 
dyanlbeads for 3 days. During the last 16h, 0.5 µCi [3H]-thymidine was added. 
 
Next we tested T cell proliferation in vivo using Ki-67 protein. Ki-67 is a nuclear 
protein associated with cell proliferation. Thus, Ki-67 is a cellular marker for 
proliferation. Mice were left untreated or treated with Dox from 5-7 weeks of age for 
8 months, and then dissected to examine the frequency of dividing cells (Ki-67+) in 
the naïve and effector CD4+ T compartments. The results showed similar Ki-67+ 
frequencies in naïve and effector CD4+ T cells, suggesting that Ptpn22 silencing 
didn’t accelerate T cell proliferations under homeostatic condition (Fig 3.15). 
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Fig 3.15 Ki-67+ cells in naïve and effector/memory T cells. Mice were treated with Dox from 5-7 
weeks for 8 months. Lymph node cells and splenocytes were stained with anti-Ki-67 mAb to determine 
the dividing cells in CD4 naïve (A) and effector (B) T cells. 
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Finally, we tested effector/memory T cell expansion potential in vivo by cell transfer 
into NOD.scid mice. Mice homozygous for the SCID mutation lack functional T and 
B cells. Thus, NOD.scid mice provide a lymphopenic environment allowing for 
expansion of exogenous cell populations. Lymph node cells were obtained from 1 
month Dox-treated WT, P2 and P4 mice. Before the transfer, the proportions of 
effector/memory T cells were determined by CD4/CD44/CD62L staining.  
 
To minimize environmental variations, WT cell were mixed with P2 or P4 cells at the 
ratio 1:1 and transferred into Dox-treated NOD.scids. The recipients were dissected 
after 1 month cell transfer to obtain lymph nodes and spleens to measure 
effector/memory T cell pool. We found before and after cell transfer, effector/memory 
T cell pools were similar in WT and P2, P4 KD CD4+ T cells, indicating Ptpn22 
silencing didn’t enhance effector/memory T cell generation and expansion in vivo 
(Fig 3.16). 
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Fig 3.16 Effector T cell expansion in the NOD.scid mice. Dox-treated WT lymph cells were mixed 
with P2, or P4 cells, and then transferred into NOD-SCIDs. The effector/memory pool in CD4+ T cells 
was measured before and after cell transfer. 
 
3.7.2.5 Ptpn22 silencing does not affect cytokine production 
In addition to hyper-proliferation of effector/memory T cells, Pep deficiency also 
increased IL-2, IL-4 and IFN-γ production in the effector T cells (Hasegawa et al., 
2004). To analyze the effect of Ptpn22 silencing on the cytokines production of T 
cells, naïve and effector CD4+ T cells were isolated from untreated or 1 month Dox-
treated mice, and then stimulated by anti-CD3/CD28 dynabeads for 3 days. 60µl 
supernatant was taken out to measure cytokines using cytometric bead array (CBA) 
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kits. Supernatant was incubated with capture beads for IFN-γ, IL-2, IL-17A, IL-10 
and IL-4, the representative cytokines of Th1, Th2, Th17 and Treg cells. Capture 
beads were then incubated with PE-detector beads. The capture beads were identified 
by the distinct combinations of APC and APC-Cy7 intensities. The standard curve 
could not be calculated due to problems during acquisition of standard samples. To 
overcome this challenge, cytokine concentrations were indicated by the geometric 
mean florescence intensity (MFI) of PE. We found Ptpn22 silencing did not alter the 
production of IL-2, IFN-γ, IL-17A, IL-10 and IL-4 in naïve T cells. In the case of 
effector T cells, no big change in IFN-γ, IL-17A, IL-10 and IL-4 production could be 
observed, but IL-2 secretion was elevated in KD effector T cells (Fig 3.17). 
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Fig 3.17 Cytokine measurement by CBA kit. Supernatant from stimulated naïve (A) and effector (B) 
CD4+ T cells were incubated with beads (CBA) to measure IL-2, IL-4, IL-10, IFN-γ and IL-17A. The 
concentration of cytokines were presented by the geometric mean florescence intensity of PE. 
 
To further verify if Ptpn22 silencing enhanced IL-2 production by effector T cells, we 
employed ELISA assay to detect IL-2 secretion. Capture antibody, which was 
precoated on the wells, could specifically bind to IL-2 in the supernatant. Wells were 
extensively washed, and then incubated with detection antibody. We found that, 
compared to effector T cells from untreated mice, IL-2 production was slightly 
increased in P2, but not P4 KD effector T cells (Fig 3.18). Similar to the CBA data, 
Ptpn22 silencing did not alter cytokine production in naïve CD4+ T cells. Ptpn22 
silencing may facilitate IL-2 production by effector CD4+ T cells, but it did not affect 
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IL-4, IL-10, IL-17A and IFN-γ production. 
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Fig 3.18 ELISA assay to detect IL-2 production of effector T cells. Effector T cells were stimulated 
with anti-CD3/CD28 dynalbeads at bead: cell ratio 1:4, 1:1 and 4:1. The supernatant was used in the 
ELISA assay to detect IL-2 concentration. 
 
3.7.3 The effect of inducible Ptpn22 silencing on Treg T cells 
We have shown that Ptpn22 silencing expanded effector/memory T cell pool only 
under priming but not under homeostatic conditions. Moreover, Pep deficient and 
knockin mice were reported to remain healthy without the development of 
autoimmune disease. These data suggested that Ptpn22 silencing may also affect 
suppressive cell populations so that effector/memory T cell generation was under 
control. Treg cells, which are pivotal in maintaining peripheral tolerance, are the 
major cell type in suppressive cell populations. Furthermore, Treg cells are 
indispensable to control diabetes in the NOD mouse. Loss of Treg cells accelerates or 
exacerbates T1D (Salomon et al., 2000; Mellanby et al., 2007). On the contrary, 
increase of Treg cells by IL-2 treatment or by genetic approaches protects and even 
reverses T1D (Peng et al., 2004; Grinberg-Bleyer et al., 2010). Given the great 
importance of Treg cells in self-tolerance, we focused on the effect of Ptpn22 
silencing on Treg cells. 
 
3.7.3.1 Long-term Ptpn22 silencing increases Treg cells  
Treg cells can be specifically identified by their unique transcription factor, FoxP3. 
To investigate the effect of Ptpn22 silencing on Treg cells, WT, P2 and P4 mice were 
left untreated or treated with Dox from 5-7 weeks old for 1 month. We first examined 
the proportion of Treg cells in CD4+ T cells. Lymph node cells and splenocytes were 
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first stained with cell surface markers, and then permeabilized, stained with anti-
Foxp3 mAb, allowing Treg cells to be determined as CD4+TCR+Foxp3+. Surprisingly, 
the frequencies of Treg cells in CD4+ T cells were significantly increased in lymph 
node cells and splenocytes, which may explain why the effector/memory T cell pool 
was not increased when Ptpn22 was silenced. Moreover, compared to the P4 KD mice, 
Treg cell expansion was increased in P2 KD mice (Fig 3.19). Our results were 
consistent with a very recent paper, reporting an increase of Treg cells in Pep KO B6 
mice (Maine et al., 2012).  
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Fig 3.19 An increase of Treg cells in the lymph nodes and spleens of KD mice. Mice were left 
untreated, or treated with Dox from 5-7 weeks old for 1 month. Treg cells were identified as 
CD4+TCR+Foxp3+ (**: P<0.01) 
 
3.7.3.2 Ptpn22 silencing enhances GITR expression on Treg cells  
We have shown that Ptpn22 silencing increased Treg cell numbers. We then 
characterized the phenotype of the expanded Treg cell compartment. Treg cells are 
characterized by the unique transcription factor FoxP3, as well as by high expression 
of several cell surface markers, including CD25, CTLA-4 and GITR. We measured 
the expression levels of these Treg cell markers by flow cytometry. We found that the 
expression levels of FoxP3, CD25 and CTLA-4 were comparable to WT. However, 
GITR expression was elevated in the P2 and P4 KD Treg cells (Fig 3.20).   
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Fig 3.20 Characterization of P2 and P4 KD Treg cells. Mice were left untreated or treated with Dox 
from 5-7 weeks old for 1month. Lymph node cells and splenocytes were used to measure the 
expression levels of CD25 (A), GITR (B), CTLA-4 (C) and FoxP3 (D). 
 
3.7.3.3 Ptpn22 silencing does not disrupt Treg cell function 
We have observed an increased Treg cell number as well as elevated GITR expression 
on Ptpn22 KD Treg cells. Another important issue was the function of Ptpn22 KD 
Treg cells. Treg cells can suppress the proliferation of conventional T cell by several 
ways: IL-2 consumption, secretion of suppressive cytokines, granzyme mediated 
cytolysis and modulation of antigen presenting cells (Shevach et al., 2009). To test the 
suppressive function of KD Treg cells, Treg cells were isolated from 1 month Dox-
treated mice. Serially diluted Treg cells were cocultured with WT conventional T 
cells (CD4+CD25-) along with 1µg/ml anti-CD3. The proliferation of conventional T 
cells was assayed by the uptake of [3H]-thymidine. We found P2 and P4 KD Treg 
cells were equally suppressive compared with WT Treg cells, indicating that Ptpn22 
silencing did not affect Treg cell function (Fig 3.21). Considering the increased 
number of Treg cells, overall Treg cell suppressive capacities were enhanced in P2 
and P4 inducible KD mice.  
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Fig 3.21 Treg assay. Treg cells were isolated and cocultured with Dox-treated WT conventional T cells 
to test the suppressive function of Treg cells. 1µg/ml anti-CD3 was used to stimulate conventional T 
cells to proliferate. 
 
3.7.3.4 The increase of Treg cells is maintained after 2 month Dox removal 
 
We have shown that 1 month Ptpn22 silencing was sufficient to increase Treg cell 
numbers. An interesting question related to whether this increase is maintained 
following Dox withdrawal. By using the inducible shNRA expression system, gene 
knockdown can be reversed by removal of Dox from the drinking water. To test the 
lifetime of expanded Ptpn22 KD Treg cells, all the mice were untreated or treated 
with Dox from 5-7 weeks of age for 1month to allow a Treg cell increase, some of 
WT, P2, and P4 mice were continuously treated for another 2 months. The other 
treated mice were given normal drinking water to shut down RNAi for another 2 
months. All the mice were then dissected to check the Treg cell proportions in CD4+ 
T cells.  Interestingly, similar to mice treated continuously for 3 months with Dox, an 
increase of Treg cells remained in the P2 mice that had been treated for 1 month then 
left untreated for 2 months. In P4 mice treated for 1 month and then left untreated for 
2 months, Treg cells were also increased in the lymph nodes and spleen, but numbers 
did not reached significance relative to Dox-treated WT (Fig 3.22). Our data indicate 
that once Treg cells were increased, Ptpn22 silencing was not required to maintain 
this increase in P2 mice, at least for 2 months. 
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Fig 3.22 The duration of Ptpn22 KD Treg cells. Mice were left untreated, or treated with Dox for 
3month or treated with Dox for 1month followed with 2month RNAi shutdown. The proportion of 
Treg cells in the lymph nodes and spleen was analyzed by flow cytometry. (*: P<0.05; **: P<0.01; 
***: P<0.001) 
 
3.7.3.5 Identifying the source of increased Treg cells in KD mice 
 
Our experiments have confirmed that Ptpn22 silencing can boost Treg cell numbers. 
One question remained as to where the additional Treg cells came from. Similarly to 
the other T cells, Treg cells develop from progenitor cells from the bone marrow, 
following education in the thymus. Most Treg cells originate in the thymus (natural 
Treg/ nTreg), and these cells express high levels of helios. In the periphery, when 
naïve T cells encounter low-dose antigen, they can be induced to differentiate into 
Treg cells (induced Treg/ iTreg) with lower helios expression (Kretschmer et al., 
2005). This differentiation can also occur by homeostatic conversion (Haribhai et al., 
2009).  In vitro, naïve CD4+ T cells can convert into Treg cells in the presence of 
TGF-β and IL-2 (Chen et al., 2003; Fantini et al., 2004). We tested all these 
possibilities to find out the reason why Ptpn22 silencing increased Treg cell numbers. 
 
 The increase of Treg cells was not due to the enhanced thymic output 
 
We first investigated Treg cell development in the thymus to find out if Ptpn22 
silencing could enhance thymic Treg cell output. Mice were left untreated, or treated 
with Dox from 5-7 weeks of age for 1 month. Mice were dissected to obtain the 
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thymi. Thymocytes were stained with fluorophore-conjugated anti-CD4, CD8, CD25, 
FoxP3 mAbs to determine Treg cells (FoxP3+). We found similar frequencies of Treg 
cells in CD4+ thymocytes, indicating Ptpn22 silencing did not affect Treg cell 
development in thymus (Fig 3.23) 
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Fig 3.23 Natural Treg cells in the thymus. Mice were left untreated, or treated with Dox from 5-7 
weeks old for 1month. The proportions of Treg cells in CD4+ T cells are shown. 
 
To further confirm the increase of Treg cells was not due to the enhanced thymic 
output, WT, P2 and P4 mice were treated with Dox from birth for 2 months. Mice 
were then dissected to measure % Treg cells in the CD4+ thymocytes.  
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Fig 3.24 Natural Treg cells in the thymus. Mice were untreated, or treated with Dox from birth for 
2month. The proportions of Treg cells in CD4+ T cells were shown. 
 
We found Ptpn22 silencing from birth also didn’t increase Treg cells in the thymus 
(Fig 3.24). Our data were distinct to a recent paper, reporting the increased Treg cells 
in Pep deficient B6 mice resulted from the enhanced thymic output (Maine et al., 
2012). The discrepancy could be attributed to either the differences in the genetic 
backgrounds of the mice used, or to the differences in the techniques employed (KO 
 82 
vs KD). In our mouse model, Ptpn22 silencing from either 5-7 weeks old or birth, did 
not affect Treg cell development. 
 
The increase of Treg cells was not due to a proliferative advantage 
 
Lyp/Pep is a negative regulator of T cell activation, thus Ptpn22 silencing likely 
enhances TCR signaling. Although Ptpn22 KD naïve and effector T cells proliferated 
normally in response to TCR stimulation, we were not sure if Ptpn22 silencing would 
enhance Treg cell proliferation and expansion. To test this possibility, Treg cells were 
isolated from untreated or 1 month Dox-treated mice. Treg cells were stimulated for 3 
days with anti-CD3/CD28 dynabeads or dendritic cells (DCs) along with anti-CD3 Ab 
and IL-2. The proliferation of Treg cells was assayed by the uptake of [3H]-thymidine. 
The result showed that P2 and P4 KD Treg cells proliferated normally (Fig 3.25A).  
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Fig 3.25 Treg cell proliferation and expansion in vitro. Treg cells were isolated from untreated or 
1month Dox-treated WT, P2 and P4 mice. Treg cells were expanded with beads or DC/anti-CD3 in 
addition to IL-2 for 3 days (A) or 10 days (B).  
 
Although we didn’t see any difference in the 3-day culture, we decided to examine the 
long-term Treg cell expansion. Loss of Pep exerted its function in a slow manner, as 
illustrated by the expanded effector/memory T cells in the older KO mice (Hasegawa 
et al., 2004). In the case of Treg cells, Ptpn22 silencing may slowly accelerate Treg 
cell turnover to increase the Treg cell number. To mimick this slow turnover in vitro, 
purified Treg cells were expanded with anti-CD3/CD28 dynalbeads or DC/anti-CD3 
for 10 days. Every 2-3 days, half of the exhausted medium was replaced with fresh 
medium to maintain cell growth. On day 10, cell numbers were counted relative to 
input cell numbers. Similar to the 3-day expansion, no differences could be seen in 
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Treg cells after 10-day expansion, indicating Ptpn22 silencing didn’t enhance Treg 
cell proliferation and expansion (Fig 3.25B). 
 
Finally we tested Treg cell proliferation capacity in vivo using Ki-67 protein. As 
mentioned above, Ki-67 could be a cellular marker for cell proliferation. Mice were 
left untreated or treated with Dox from 5-7 weeks old for 8 months, and then 
dissected to examine the dividing cells (Ki-67+) among Treg cells. We found Ki-67+ 
frequencies among Treg cells were comparable between WT and KD mice, indicating 
Ptpn22 KD Treg cells divided normally in vivo (Fig 3.26). This observation coupled 
with the in vitro Treg cell expansion data, led us to believe that the increased Treg cell 
frequencies were not due to any proliferative advantage of KD Treg cells. 
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Fig 3.26 The frequencies of Ki-67+ in Treg cells. Mice were untreated, or treated with Dox from 5-7 
weeks old for 8months. Treg cells were gated on CD4+FoxP3+ cells. The frequenciese of Ki-67+ in 
Treg cells are shown. 
 
The increase of Treg cells was not due to increased  naïve T cell conversion in vitro 
 
Depending on culture conditions, naïve CD4+ T cells can differentiate into Th1, Th2, 
Th17 or Treg cells. When activated naïve CD4+ T cells are cocultured with TGF-β 
and IL-2, they can convert into FoxP3+ Treg cells (Chen et al., 2003; Fantini et al., 
2004). We investigated if the increase of Treg cells was due to enhanced naïve T cell 
conversion in response to TGF-β. Naïve CD4+ T cells were purified and then induced 
to convert into Treg cells. 3 days later, cells were harvested and stained with anti-
FoxP3 mAb. Comparable converted Treg cell percentages could be found in control 
(untreated and Dox-treated WT) and P2 KD cells (Fig 3.27). Thus, the Treg cell 
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increase could not be explained by differences in naïve T cell differentiation in 
response to TGF-β. 
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Fig 3.27 Naïve T cell differentiation into Treg in vitro. Naïve CD4+ T cells were cocultured with TGF-
β and IL-2 to induce conversion into Treg cells. 3 days later, cells were harvested and stained with anti-
FoxP3 to analyze Treg cell proportion. 
 
The increase of Treg cells was not due to enhanced homeostatic conversion in vivo 
 
Our data have shown that the increase of Treg cells did not result from increased T 
cell development in the thymus, a proliferative advantage, or naïve T cell conversion 
in response to TGF-β. We next examined if the Treg cell increase was due to 
homeostatic conversion in vivo. By microarray analysis, Feuerer and colleagues found 
that homeostatically converted Treg cells could be defined as CD103+Klrg1+ Treg 
subset (Feuerer et al., 2010).  
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Fig 3.28 The proportions of homeostatic converted Treg cells. Mice were left untreated or treated with 
Dox for 1month. Splenocytes were stained with anti-CD103 and Klrg1 to determine homeostatic 
converted Treg cells (CD103+Klrg1+). 
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We stained lymph node cells and splenocytes with fluorophore-conjugated anti-
CD103 and Klrg1 mAbs to measure the frequencies of homeostatically converted 
Treg cells. Again, no differences could be seen in the CD103+Klrg1+ Treg subset, 
indicating that Ptpn22 silencing didn’t enhance homeostatic conversion in vivo (Fig 
3.28). 
 
Since Helios is thought to be preferentially expressed in thymus-derived Treg cells, 
we additionally investigated Helios expression in Treg cells. Consistent with the 
results presented above, similar percentages of Helios negative Treg cells could be 
observed in KD mice with and without treatment (Fig 3.29). Thus, the increase of 
Treg cells was not due to enhanced homeostatic conversion in vivo. 
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Fig 3.29 The proportions of Helios negative Treg cells. Mice were left untreated or treated with Dox 
for 1month. Splenocytes were stained with anti-CD4, FoxP3 and Helios mAbs to determine Helios 
negative Treg cells. 
 
3.8 The effect of inducible Ptpn22 silencing on chemokine receptors 
 
Several papers have reported the importance of chemokines and chemokine receptors 
in the development off diabetes in the NOD mouse (Frigerio et al., 2002; Morimoto et 
al., 2004; Rhode et al., 2005; Grewal et al., 1997). Considering that Ptpn22 is 
predominantly expressed in T and B lymphocytes, we focused on the expression of 
chemokine receptors in CD4+ T cells. Chemokine receptors belong to the G-protein 
coupled receptor superfamily. Through the PI(3)K-Dock2-Rac pathway, chemokine 
receptors can induce cell cytoskeleton rearrangement, cell polarization, and cell 
migration (Weiss-Haljiti C et al., 2004; Viola A et al., 2007). Several chemokine 
receptors, such as CXCR3, CCR4, and CCR5, have been confirmed to play roles in 
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mediating T cell trafficking in diabetes pathogenesis. Loss of CXCR3 protected mice 
from LCMV infection induced diabetes (Frigerio et al., 2002). Similarly, CCR5 
neutralization abrogated β cell destruction and diabetes (Carvalho-Pinto et al., 2004). 
Overexpression of CCL22, a CCR4 ligand, in the pancreas from birth accelerated 
diabetes (Kim et al., 2002), though its overexpression from 8 weeks of age prevented 
the disease through enhanced recruitment of Treg cells into pancreas (Montane et al., 
2011).  
 
Given the importance of chemokine receptors in the pathogenesis of T1D, we 
examined the effect of Ptpn22 silencing on chemokine receptors in T cells. Lymph 
node cells and splenocytes were obtained from 1 month Dox-treated mice. Cells were 
stained with fluorophore-conjugated anti-CD4, CD25, CD62L, CCR4, CCR5 and 
CXCR3 mAbs to measure chemokine receptor expression on Treg and effector CD4+ 
T cells. We found that the expression of CXCR3, CCR4 and CCR5 were not affected 
in lymph node cells (data not shown). More CCR4 and CXCR3 were expressed on the 
Treg (CD4+CD25+) cells from P2, but not P4 KD splenocytes. Interestingly, CCR4, 
CCR5 and CXCR3 were expressed normally on the P2 and P4 KD effector/memory T 
cells (Fig 3.30). Our data showed that Ptpn22 silencing mainly affects chemokine 
receptor expression on Treg cells by enhancing CCR4 and CXCR3 expression.  
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Fig 3.30 The expression of chemokine receptors, CCR4, CCR5 and CXCR3 on splenic Treg and 
effector/memory CD4+ T cells. Mice were left untreated, or treated with Dox for 1month. Splenocytes 
were stained with fluorophore-conjugated anti-CD4, CD25, CD62L, CCR4, CCR5 and CXCR3 mAbs 
to measure chemokine receptor expression (**: P<0.01; *: P<0.05) 
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3.9 The effect of inducible Ptpn22 silencing on B cells 
In humans, several reports confirmed that Lyp changes the composition and function 
of the B cell compartment. Lyp participates in the removal of autoreactive B cells 
(Menard et al., 2011). Heterozygous subjects for Lyp R620W had more IgD+CD27- B 
cells (Habib et al., 2012) as well as reduced IgD+CD27+ (memory) B cells in 
peripheral blood (Rieck et al., 2007). BCR signaling was deficient, as illustrated by 
decreased phosphorylation, calcium flux and impaired proliferation (Arechiga et al., 
2009). In mouse, loss of Pep enhanced B cell proliferation (Hasegawa et al., 2004). In 
this project, we investigated the effect of Ptpn22 silencing on B cell activation, 
proliferation, survival as well as T-B interaction.  
 
3.9.1 Ptpn22 silencing enhances B cell activation and proliferation 
 
As mentioned above, several papers have examined the role of Lyp/Pep on B cells. To 
investigate the role of Pep on B cells in the NOD mouse, we examined KD B cell 
activation and proliferation. Once cells were activated, CD69 expression was 
upregulated in the early response and then went down. Subsequently, CD25 
expression was elevated.  
 
B cell activation was assayed by activation markers CD25 and CD69. Mice were 
treated with Dox from 5-7 weeks of age for nearly 1 month. B cells were purified 
from splenocytes using anti-CD19 (positive selection) or anti-CD43 microbeads 
(negative selection) (Miltenyi). B cells were then stimulated with LPS, serially diluted 
anti-IgM F(ab)’2 or anti-CD40. 1 day later, cells were harvested, and stained with 
anti-CD25/CD69 mAbs to examine B cell activation. 2 days after stimulation, [3H]-
thymidine was added into wells to test B cell proliferation. We found in response to 
anti-IgM F(ab)’2 and anti-CD40, P2 and P4 KD B cells expressed more CD25 and 
CD69, illustrated by the increased MFI of CD25 and CD69, as well as elevated 
percentages of CD25+CD69+ B cells (Fig 3.31). Due to the higher KD efficiency in P2 
KD mice, increased activation could be observed in P2 KD cells compared to P4 KD 
B cells.  
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Fig 4.31 B cell activation. B cells were isolated from 1month Dox-treated mice, and then stimulated 
with LPS, serially diluted anti-IgM F(ab)’2 or anti-CD40. 1 day later, B cell activation was assayed by 
activation markers, CD25 and CD69. A. C. E shows CD25 MFI, CD69 MFI, and % CD25+CD69+ in B 
cells in response to anti-IgM F(ab)’2. B. D. F shows CD25 MFI, CD69 MFI, and % CD25+CD69+ in B 
cells in response to anti-CD40. 
 
We assayed B cell proliferation after 2 day stimulation. Similar to the Ptpn22 KO and 
knockin B cells, Ptpn22 silencing enhanced P2 B cell proliferation in response to anti-
IgM F(ab)’2 or anti-CD40 (Fig 3.32A,B). P2 and P4 KD B cells proliferated normally 
in response to LPS, a Toll-like receptor stimulant (Fig 3.32C). 
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Fig 3.32 B cell proliferation. B cells were isolated from untreated or 1month Dox-treated mice, and 
then stimulated with LPS, serially diluted anti-IgM F(ab)’2 or anti-CD40. 2 days later, B cell activation 
was assayed by the uptake of [3H]-thymidine. A. B cell proliferation in response to anti-IgM F(ab)’2; B. 
to anti-CD40; C. to LPS. 
 
3.9.2 Ptpn22 silencing facilitates PLC-γ2 phosphorylation 
In humans, PLC-γ2 phosphorylation was attenuated when B cells carried PTPN22 
heterozygous allele (Arechiga et al., 2009; Habib et al., 2012). Since we saw 
enhanced B cell activation and proliferation when Ptpn22 was silenced, to give more 
details, we decided to examine PLC-γ2 phosphorytion which was involved in the 
BCR signaling. For this purpose, splenocytes were prepared from untreated or 1 
month Dox-treated mice, and stimulated with 20µg/ml anti-IgM F(ab)’2 for 1, 3, 5 or 
10min. Cells were fixed immediately after stimulation, permeabilized and then 
stained with anti-CD19 and phos-PLC-γ2 mAbs. PLC-γ2 phosphorylation was 
determined by using the geometric mean fluorescence intensity of phos-PLC-γ2. We 
found phos-PLC-γ2 MFI dramatically went up in the first 1 min stimulation, and then 
decreased. Ptpn22 silencing in P2 mice enhanced PLC-γ2 phosphorylation in almost 
all the time points we checked. We didn’t see enhanced PLC-γ2 phosphorylation in 
P4 KD B cells, maybe due to the reduced KD efficiency in comparison to the P2 cells 
(Fig 3.33). 
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Fig 3.33 PLC-γ2 phosphorylation in response to anti-IgM F(ab)’2. Splenocytes were prepared from 
untreated or 1 month Dox-treated mice, and stimulated with 20µg/ml anti-IgM F(ab)’2 for different 
time intervals. Cells were fixed immediately after stimulation, permeabilized and then stained with 
anti-CD19 and phos-PLC-γ2 mAbs. PLC-γ2 phosphorylation was determined using the geometric MFI 
of phos-PLC-γ2. 
 
3.9.3 Ptpn22 silencing increases B cell apoptosis in response to stimulus 
In humans, B cells bearing heterozygous Ptpn22 allele survived better than WT B 
cells (Habib et al., 2012). We tested B cell apoptosis by using the cell viability dye 7-
AAD. In late apoptotic cells, cell membrane is compromised allowing the uptake of 7-
AAD. Hence, the late apoptotic cells were marked as 7-AAD+.  
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Fig 3.34 B cell apoptosis. B cells were isolated from 1month Dox-treated mice, and then stimulated 
with serially diluted anti-IgM F(ab)’2 (A) or anti-CD40 (B). 1 day later, the proportion of live (7-AAD-
) B cells was assayed. 
 
We obtained spleens from 1-month Dox-treated mice. B cells were purified from 
splenocytes, and then stimulated with serially diluted anti-IgM F(ab)’2 or anti-CD40. 
1 day after stimulation, apoptotic B cells were determined as B220+7-AAD+. 
Interestingly, Ptpn22 silencing accelerated cell apoptosis in response to anti-IgM 
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F(ab)’2 and anti-CD40 stimulation. Moreover, more dead cells could be found in P2 
KD than P4 KD B cells (Fig 3.34).  
 
3.9.4 Ptpn22 silencing doesn’t alter B cell composition 
 
B cells are a heterogeneous cell population. We have shown that Ptpn22 silencing 
enhanced B cell activation, proliferation, apoptosis and PLC-γ2 phosphorylation in 
response to anti-IgM F(ab)’2 and anti-CD40. We further tested if Ptpn22 silencing 
could alter B cell composition in bone marrow (BM), peritoneal cavity (PC) and 
spleen (SP). Since a stronger phenotype could be observed in P2 KD mice, we just 
compared cell compositions in Dox-treated WT and P2 mice. 
 
B cell composition in BM 
 
B cells mature in the bone marrow. According to their expression of IgD, IgM and 
B220, B cells in the BM can be divided into mature B cells (IgM+IgD+), immature B 
cells (IgM+IgDint), Pre B (IgM-IgD- B220-) and Pro B (IgM-IgD- B220+).  We 
compared the proportions of each subset in BM. No differences could be observed in 
any of the subsets, indicating that Ptpn22 silencing didn’t alter cell composition in 
BM (Fig 3.35). 
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Fig 3.35 B Cell composition in BM of Dox-treated WT and P2 mice. The proportions of mature B cells 
(IgM+IgD+), immature B cells (IgM+IgDint), Pre B (IgM-IgD- B220-) and Pro B (IgM-IgD- B220+) are 
shown. A. Schematic of B cell subsets gating B.C. The statistics of each B cell subset. 
 
B cell composition in PC 
 
We next analyzed B cell subsets in the peritoneal cavity (PC), in which an abundance 
of B1a cells could be found. CD5 is selectively expressed on B1a cells. CD43 is not 
expressed on most B cells, which is used in the gating of B2 cells. Thus, B cells were 
first plotted against CD43 and CD5 to identify B1a (CD5+), B1b (CD43+CD5-) and 
B2 (CD43-CD5-) cells. B2 cells were further plotted against CD21 and CD23 to 
determine marginal zone (MZ, CD43-CD5- CD23-CD21+) and follicular (FO, CD43-
CD5- CD23+CD21+) B cells. We found that the proportion of each subset was quite 
similar in Dox-treated WT and P2 mice, suggesting Ptpn22 silencing didn’t alter cell 
composition in PC (Fig 3.36). 
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Fig 3.36 B Cell composition in PC of Dox-treated WT and P2 mice. The proportions of B1a (CD5+), 
B1b (CD43+CD5-), B2 (CD43-CD5-), MZ (CD43-CD5-CD23-CD21+) and FO (CD43-CD5- CD23+ 
CD21+) are shown. A. Schematic of B cell subsets gating B.C. The statistics of each B cell subset. 
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B cell composition in SP 
 
We further analyzed B cell subsets in spleen (SP) by two different approaches. We 
measured mature (IgM+IgD+) and immature (IgM+IgD-) B cells by anti-IgM and IgD 
staining. Again, no difference could be observed (Fig 3.37).  
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Fig 3.37 Mature and immature B cells in spleen. The proportions of mature B cells (IgM+IgD+) and 
immature B cells (IgM+IgD-) are shown. A. Schematic of B cell subsets gating B. The statistics of each 
B cell subset. 
 
In the second approach, B cells were first plotted against CD1d/CD5 to determine 
regulatory B cells (CD1dhiCD5+) or CD43/CD5 to identify B1a (CD5+), B1b 
(CD43+CD5-) and B2 (CD43-CD5-) cells. B2 cells were next plotted against CD93 
and CD23 to determine T1 (CD43-CD5- CD23-CD93+), T2 (CD43-CD5- 
CD23+CD93+) and MZ+FO (CD43-CD5- CD93-) B cells. MZ+FO B cells were 
further plotted against CD23 and CD21 to identify FO (CD43-CD5- CD93-
CD23+CD21int) and MZ (CD43-CD5- CD93-CD23-CD21+) B cells. Interestingly, 
elevated FO and reduced MZ B cells could be found in the Dox-treated P2 
splenocytes. Other cell subsets, like B1a, B1b, regulatory B cells and total B cells 
were not altered (Fig 3.38). 
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Fig 3.38 B Cell composition in spleen of Dox-treated WT and P2 mice. The proportions of regulatory 
B cells (CD1dhiCD5+), B1a (CD5+), B1b (CD43+CD5-), FO (CD43-CD5- CD93-CD23+CD21int), MZ 
(CD43-CD5- CD93-CD23-CD21+) and total B cells are shown. A. Schematic of B cell subsets gating B. 
The statistics of each B cell subset (*,: P<0.05). 
 
3.9.5 Ptpn22 silencing doesn’t affect T-B interactions in GC 
As a subset of antigen presenting cells (APCs), B cells present both costimulatory and 
inhibitory signals to induce T cell activation or anergy (Alegre et al., 2001) (Fig 4.39). 
We investigated the role of Ptpn22 KD on the interaction between B cells and T cells. 
To examine if Ptpn22 silencing could affect the expression of costimulatory and 
inhibitory molecules on B cells, B cells were prepared from 4-5 month Dox-treated 
WT and P2 mice. B cells were then stained with fluorophore-conjugated anti-CD80, 
CD86, MHC, CD40, PD-L1 and PD-L2 mAbs to analyze costimulatory and inhibitory 
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signals on B cells. The results showed that the expression levels of CD80, CD86, 
CD40, MHCII, PD-L1, and PD-L2 were comparable between Dox-treated WT and P2 
B cells, indicating that Ptp22 silencing did not affect the antigen presenting ability of 
B cells (Fig 4.40). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.39 Costimulatory and inhibitory molecules on APCs, including B cells. Costimulatory signals are 
in the red rectangle, and inhibitory signals are shown in the green rectangle. 
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Fig 3.40 Costimulatory and inhibitory molecules on B cells. Mice were treated with Dox for 4-5 
months. B cells were stained with mAbs to measure the expression levels of CD80, CD86, MHCII (A), 
CD40, PD-L1 (B). The % of PD-L2+ in B cells were shown in (C). 
 
We further analyzed T-B cell interaction in the germinal center (GC). Follicular 
helper T (TFH) cells, which highly express CXCR5 and Bcl-6, represents a T cell 
subset preferentially in the germinal center. TFH cells provide crucial signals to 
germinal center B cells (peanut agglutinin positive, PNA+) to regulate humoral 
immunity (Chung et al., 2011; Linterman et al., 2011; Oestreich et al., 2012). We 
analyzed Treg and effector CD4+ T cells of TFH  cells in 5 month Dox-treated mice, as 
well as the germinal center B cells in 8 month Dox-treated mice. The results showed 
that Ptpn22 silencing did not alter the frequencies of follicular Treg or effector CD4+ 
T cells (Fig 3.41A,B). The proportions of PNA+ germinal center B cells were also 
similar in Dox-treated WT and P2 mice (Fig 3.41C). These data demonstrated that 
Ptpn22 silencing did not affect T-B interactions in the germinal center. 
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Fig 3.41 The follicular Treg, follicular effector T cells and germinal center B cells in the KD mice. 
Mice were treated with Dox for 5 or 8 months. Effector and Treg cells of CXCR5+ follicular helper T 
cells in lymph nodes (A) and spleen (B) are shown. The frequencies of germinal center (PNA+) B cells 
in the splenocytes were compared in Dox-treated WT and P2 mice. 
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To sum up, we observed enhanced B cell activation, proliferation and apoptosis in 
response to anti-IgM F(ab)’2 or anti-CD40. An elevated PLC-γ2 phosphorylation 
could be detected in the P2 KD B cells. Moreover, increased FO B cells and reduced 
MZ B cells could be detected in P2 KD splenocytes.  Ptpn22 silencing did not alter B 
cell composition in the peritoneal cavity, bone marrow as well as costimulatory and 
inhibitory signals on B cells. The T-B interaction in germinal center was also 
unaffected.  
 
In humans, several reports showed that in subjects bearing heterozygous Lyp R620W, 
BCR signaling was deficient, as illustrated by decreased PLC-γ2 phosphorylation, 
calcium flux and impaired proliferation (Arechiga et al., 2009; Habib et al., 2012). In 
mouse, loss of Pep enhanced B cell proliferation (Hasegawa et al., 2004). Our results 
support the proposal that the Lyp R620W variant in humans is a gain-of-function 
mutation, as Ptpn22 silencing in the NOD mice showed an opposite phenotype to that 
observerd in humans. 
 
3.10 The effect of inducible Ptpn22 silencing on DC and MΦ  
As mentioned above, antigen presenting cells (APCs) are essential for T cell 
activation and immune tolerance. Both co-stimulatory and inhibitory molecules are 
expressed on APCs (Alegre et al., 2001). 
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Fig 3.42 Costimulatory and inhibitory molecules on DC and MΦ. Mice were left untreated or treated 
with Dox from 5-7 weeks old for 4-5 months. Splenic DC and MΦ were stained with mAbs to measure 
the expression levels of CD80, CD86, MHCII (A,C), CD40 and PD-L1 (B,D).  
 
Besides T and B cells, Ptpn22 can also modulate dentric cells (DCs) and macrophages 
(MΦ). Zhang and colleagues reported that in the Ptpn22 knockin mouse, more CD40 
was expressed on DCs, which may facilitate effector/memory T cell generation 
(Zhang et al., 2011). In this project, we examined APC function by measuring 
costimulatory and inhibitory molecules in untreated or 4-5 month Dox-treated mice. 
Contrary to the Ptpn22 knockin mouse, Ptpn22 silencing did not affect costimulatory 
and inhibitory molecules on DC and MΦ (Fig 3.42). 
 
3.11 The effect of inducible Ptpn22 silencing on colitis and diabetes 
In humans, Lyp-620W variant increased disease susceptibility to type 1 diabetes, 
arthritis, and many other autoimmune diseases. However, the Ptpn22 knockout and 
knockin mice were healthy in spite of increased effector/memory T cell pool and 
enhanced B cell responsiveness, which failed to explain the increased disease 
susceptibility in humans. Moreover, so far it is controversial whether Lyp-620W is a 
gain- or loss-of-function variant (Vang et al., 2005; Rieck et al., 2007; Aarnisalo et 
al., 2008; Zhang et al., 2011). In this project, we investigated the role of Ptpn22 in 
two autoimmune diseases using inducible RNAi: type 1 diabetes and colitis. The 
reason why we chose these two diseases is that the Lyp-620W allele modulates 
diabetes and colitis in antagonitic ways in humans: the 620W variant increases 
susceptibility to diabetes but protects from Crohn’s disease (Bottini, et al., 2004; 
Smyth et al., 2004; Ladner et al., 2005; Onengut-Gumuscu et al., 2004; Diaz-Gallo et 
al., 2011).  By using these two autoimmune disease models, we aimed to interpret the 
role of Ptpn22 more precisely.  
 
Ptpn22 silencing exacerbated colitis in a T cell transfer model 
 
To investigate the role of Pep in colitis, CD4+CD45RBhi cells were purified from 2 
month Dox-treated WT, P2 and P4 mice. Briefly, CD4+ T cells were first isolated 
from splenocytes using CD4+ T cell isolation kit (Miltenyi). CD4+ T cells were then 
incubated with biotinylated anti-CD45RBhi, washed and separated using anti-biotin 
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microbeads. Purified CD4+CD45RBhi cells were injected i.v. into NOD.scid mice. 6-7 
weeks after transfer, the recipients were dissected to obtain the colon. Colon tissues 
were fixed, embedded in paraffin, cut and stained with Haematoxylin and Eosin 
solutions (H&E). 
 
Haematoxylin specifically stains the chromatin and nuclear membrance within 
nucleus of the cells, Eosin stains cytoplasm, muscle fibers and collagen to define cell 
and tissue shapes. Under microscope, dark reddish orange colors identified red blood 
cells; ligher pastel pink determined collagen; and bright pink identified smooth 
muscle. By using H&E staining, we could score the inflammation and cell 
infiltrations in the colon (with kind help from Dr. Alma Zernecke). Our results 
showed that 6-7 weeks after transfer, CD4+CD45RBhi cells could efficiently induce 
colitis in the NOD.scid mice. Compared to the recipients with WT cells, increased 
severity was seen in mice transferred with the P4 KD cells (Fig 3.43).  
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Fig 3.43 Inflammation severity in the colon of NOD.scid recipients. NOD.scid mice were transferred 
with Dox-treated WT, P2 and P4 CD4+CD45RBhi cells. 6-7 weeks after transfer, colon tissues were 
obtained and scored by H&E staining. 
 
Ptpn22 silencing protected P2 mice from diabetes 
 
Ptpn22 silencing exacerbated colitis in the NOD.scid transfer model. We further 
explored the role of Ptpn22 in autoimmune diabetes by two different approaches: 
spontaneous diabetes and CY induced diabetes. In the spontaneous diabetes test, WT, 
P2 and P4 mice were left untreated, or treated with Dox from 4 or 10 weeks old to 
determine the time window for Pep function. The results from P2/WT mice treated 
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with Dox from 4 weeks were not entirely reliable, due to observed effect on diabetes 
frequency in WT mice. This was absent in mice treated from 10 weeks. Only results 
from P2 groups treated from 10 weeks are shown. Compared to the untreated WT, P2, 
and Dox-treated WT, diabetes incidence was significantly decreased in the Dox-
treated P2 mice (Fig 3.44A). However, this protection could only be observed in the 
Dox-treated P2, but not P4 KD mice from 10 weeks old (Fig 3.44B), and even in the 
P4 KD mice treated from an earlier time point of 4 weeks old (Fig 3.44C). The 
discrepancy between P2 and P4 KD mice will be discussed later. 
 
Fig 3.44 Spontaneous diabetes test. WT, P2 and P4 mice were left untreated, or treated with Dox from 
10 weeks of age (A, B) or 4 weeks old (C). A: WT-dox n=20 ; P2-dox n=31 ; WT+dox n=15; P2+dox 
n=18; B: WT-dox n=36 ; P4-dox n=29 ; WT+dox n=20 ; P4+dox n=15; C: WT-dox n=36 ; P4-dox 
n=29 ; WT+dox n=32; P4+dox n=34; Log-rank test for A: WT-dox vs. P2-dox P=0.26 ; WT+dox vs. 
P2+dox P=0.006; P2-dox vs. P2+dox P=0.0418. Mice were tested diabetes from 3 months of age once 
a week until they became diabetic or reached 7 months of age (*: P<0.05) 
 
Given the significant role played by Treg cells in immune tolerance, it was likely that 
the diabetes protection in P2 KD mice was due to the increased numbers of Treg cells. 
Cyclophosphamide (CY) can induce diabetes by reducing Treg cells. The idea was 
Ptpn22 silencing increased Treg cells in the KD mice. After CY treatment, more Treg 
cells would remain in the KD mice, and thereby protect from or delay diabetes. Since 
we only saw the diabetes protection in the P2 KD mice, WT and P2 mice were treated 
with Dox for at least 1 month, and then injected i.p. with 200µg CY/g body weight. 
Consistent with the spontaneous diabetes result, P2 KD mice were protected from CY 
induced diabetes (Fig 3.45).  
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Fig 3.45 Cyclophosphamide induced diabetes in the 1month Dox-treated WT and P2 mice. Mice were 
tested for diabetes every two days with Diastix (Bayer). WT+dox n=15; P2+dox n=11. 
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Autoimmune diseases are characterized by the dysfunction of the immune system – 
the failure of the immune system to remain tolerant to self-antigen and its 
subsequently aberrantly attack of self-tissues or -organs. There are a multitude of 
autoimmune diseases, including type 1 diabetes, rheumatoid arthritis (RA), juvenile 
idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), Graves’ disease, 
generalized vitiligo and Hashimoto’s thyroiditis. Type 1 diabetes is characterized by 
the infiltration of immnue cells into the pancreas and by the permanent destruction of 
insulin producing β cells. Unlike for many other autoimmune diseases, men and 
women are almost equally susceptible to type 1 diabetes. The mean age of disease 
onset is 12 years old. Although multiple factors, including diet, commensal bacterial 
and viral infection, can influence the susceptibility to type 1 diabetes, the disease 
predisposition in children is mainly imparted by genetics.  
 
To identify the genetic variations linked to the disease susceptibility, genome-wide 
association studies (GWAS) have been carried out. GWAS provides a powerful tool 
to dramatically accelerate the discovery of new risk genetic factors in type 1 diabetes. 
So far, more than fifty single-nucleotide polymorphisms (SNPs) have been identified 
according to the growing database (www.t1dbase.org). Among these 50 loci, the gene 
PTPN22 ranks first in the non-HLA genetics risk factors. The disease susceptibility of 
PTPN22 is imparted by the SNP (C1858T), which causes a substitution from arginine 
to tryptophan at the 620 position (Lyp-620R to Lyp-620W). Besides type 1 diabetes, 
the disease associated variant Lyp-620W is a strong risk factor in many other 
autoimmune diseases, including rheumatoid arthritis (RA) (Orozco et al., 2005; van 
Oene et al., 2005; Wesoly et al., 2005), juvenile idiopathic arthritis (JIA) (Hinks et al., 
2005), systemic lupus erythematosus (SLE) (Kyogoku et al., 2004), Wegener’s 
granulomatosis (Jagiello et al., 2005), Graves’ disease (Velaga et al., 2004) and  
generalized vitiligo (Canton et al., 2005). Very interestingly, Lyp-620W is a 
protective allele in Crohn’s disease, however, the mechanism of this protection is 
unknown (Frank et al., 2011; Rivas et al., 2011; Diaz-Gallo et al., 2011).  
 
Although nearly 50 risk factors have been identified, little is known about how most 
of these genetic variants accelerate or exacerbate type 1 diabetes. In this project, we 
chose to study the role of PTPN22 in type 1 diabetes, because of its broad association 
with multiple autoimmune diseases. Substantial efforts have been made to clarify how 
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the disease susceptible variant contributes to the pathogenesis of autoimmune 
diseases. The first study in 2004 found that Lyp-620W disrupted the interaction 
between Lyp and CSK (Bottini, et al., 2004). Subsequent studies demonstrated that T 
cells, as well as B cells from peripheral blood of subjects heterozygous at PTPN22, 
are less responsive, illustrated by the reduced phosphorylation in the TCR/BCR 
signaling compenents, reduced IL-2 production, impaired calcium flux and 
proliferation deficit in response to stimulation (Vang et al., 2005; Rieck et al., 2007; 
Aarnisalo et al., 2008; Habib et al., 2012). When two Lyp variants were transfected 
into Jurkat T cells, Lyp-620W showed decreased NF-AT/AP-1 activity (Vang et al., 
2005). Notably, an inhibitor against Lyp could recover TCR/BCR deficit as found in 
heterozygous subjects. These data strongly support the notion that Lyp-620W is a 
gain-of function variant. Recently, a notable study indicated that Lyp-620W might 
instead be a loss-of-function variant. In support of this hypothesis, Pep-619W (the 
mouse homolog of human Lyp-620W) knockin mice resemble the KO phenotype, 
possibly due to the accelerated Lyp protein degradation (Zhang et al., 2011). 
Zikherman and colleagues also found enhanced Erk phosphorylation when Lyp-620W 
was introduced into Jurkat T cells (Zikherman., 2009). So far, whether Ptpn22 
R620W is a gain- or loss-of-function mutation is still controversial. To address this 
issue, we generated two transgenic NOD mouse lines (P2 and P4) in which Ptpn22 
can be inducibly silenced.  
 
PTPN22 encodes a negative regulator of TCR/BCR signaling. Loss of Ptpn22 boosts 
effector/memory T cells and serum antibody levels, especially in older mice 
(Hasegawa et al., 2004). Despite being predisposed to autoimmunity, KO mice are 
healthy and even protected from EAE, which may be due to increased Treg cell 
numbers in the thymus and periphery (Maine et al., 2012). Similarly, we observed an 
increase of Treg cells in the lymph nodes and spleens of KD mice. Contrary to the 
findings in KO mice, the elevated thymic Treg cells could not be observed in either 
adult KD mice or KD mice treated from birth. Notably, complete loss of Ptpn22 
causes a more substantial increase of Treg cells than Ptpn22 KD. These differences 
could be due to the partial loss of Ptpn22 in our inducible KD mice and additive 
effect of greater thymic output in the KO mice. Nevertheless, the increase of Treg 
cells in the peripheral organs of KD mice demonstrates that Ptpn22 participates in the 
regulation of peripheral homeostasis of Treg cells.  
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Most Treg cells are derived from the thymus (Foxp3+Helios+). In the periphery, naïve 
CD4 T cells can convert into Treg cells (iTreg) under some circumstances.  Since we 
did not observe elevated output of thymic Treg cells, we focused on whether Ptpn22 
silencing could specifically increase iTreg cell numbers in the periphery. 
Interestingly, we found that Ptpn22 silencing did not increase naïve T cell conversion 
into iTreg cells, as illustrated by comparable numbers of iTreg cells (Helios -) in vivo, 
comparable iTreg cell conversion by TGF-β in vitro, and no change in 
homeostatically converted iTreg cells (CD103+Klrg1+). Although recent studies 
reported that some iTreg cells also express Helios, the frequency of Helios negative 
Treg cells remains almost the same, indicating nTreg and iTreg cells are equally 
increased (Gottschalk et al., 2012). The increase of Treg cells in KD mice might not 
be due to the elevated proliferative capacity. First, in vitro we did not observe the 
enhanced proliferation either during 3-day or 10-day expansion.  Second, in vivo the 
proportion of dividing Treg cells (Ki-67+) was comparable after Ptpn22 silencing. We 
think the increase of Treg cells might be due to the enhanced responsiveness to IL-2. 
Grinberg-Bleyer and colleagues reported that a low dose of IL-2 administration 
reverses diabetes by specifically increasing Treg cells (Grinberg-Bleyer et al., 2010). 
We found that IL-2 production by P2 KD effector T cells is slightly increased, which 
could constitute a source of IL-2 for Treg cells in KD mice. In addition, Ptpn22 
silencing could enhance homeostatic TCR signaling and decreases the requirement of 
Treg cell for IL-2, which then slowly accelerates the turnover of Treg cells and 
increase Treg cell numbers (Josefowicz et al., 2012). 
 
We think the disease resistance in P2 KD mice is imparted, at least partially, by the 
increased frequency of Treg cells. In support of this notion, P2 KD mice are still 
protected from diabetes after Cyclophosphamide (CY) administration. CY induces 
diabetes by depleting Treg cells. After CY depletion, more Treg cells remained in P2 
KD mice, imparting disease protection. This suggests a link between the increased 
number of Treg cells and the observed protection from autoimmune diabetes, similar 
to the protection from EAE observed in the KO mice.  
 
Some discrepancies can be observed between KO and KD mice. Unlike its effect on 
Treg cells, Ptpn22 silencing did not affect the expansion of effector T cells in adult 
KD mice. We observed similar effector/memory T cell pools in adult WT and KD 
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mice treated for up to 8 months Dox. In support of this observation, we found Ptpn22 
KD effector and naïve CD4 T cells proliferate normally in vitro, with similar 
frequencies of dividing (Ki-67+) cells in vivo. Our findings in Ptpn22 KD mice are 
distinct from those in KO and knockin mice, in which enhanced effector T cell 
expansion was observed both in vitro and in vivo. This difference could be due to the 
incomplete loss of Ptpn22, but more likely, due to the unaltered thymocyte 
development in our KD adult mice. In this project, Ptpn22 was silenced from 5-7 
weeks of age, when most thymocytes have already matured (Scollay et al., 1980). In 
support of this hypothesis, Ptpn22 silencing from birth significantly boosts 
effector/memory T cells after 2 months of treatment, resembling the effector T cell 
phenotype found in KO and knockin mice. Indeed, Ptpn22 is involved in the thymus 
selection and loss of Ptpn22 enhances positive selection, but does not alter negative 
selection (Hasegawa et al., 2004). Our data suggest that Pep modulates effector T cell 
generation and expansion mainly at the level of thymic development. Future 
experiments with TCR transgenic mice on the NOD background will help explore if 
Ptpn22 silencing can alter positive and negative selections in the NOD mice. 
Alternative approaches will also be applied to examine if TCR repertoire is changed 
after Ptpn22 silencing. For example, we can use FACS staining to investigate the 
TCR beta chain utilization, or compare the proliferative capacity of thymocytes from 
WT/KD mice treated from birth.  
 
Although the effector/memory T cell pool is retained in adult KD mice, we found that 
Ptpn22 silencing indeed increases homeostatic TCR signaling in effector T cells. In 
vivo anti-CD3 stimulation strongly induced effector T cell generation in KD mice 
pretreated for 10 days. The enhanced effector T cell generation depended on TCR 
stimulus, as it was not seen in the setting of lymphopoenia-induced expansion when 
lymph node cells were transferred into NOD.scid mice. It seems that Ptpn22 silencing 
elevates homeostatic signals in both effector and Treg cells. But in adult KD mice, 
effector T cells fail to expand possibly due to the increased Treg cell numbers. To test 
this hypothesis in future, the effector/memory T cell pool will be investigated in Treg 
depleted mice (by administrating CD25 depletion antibody). 
 
Interestingly, our data provide the first evidence for a role of Ptpn22 in chemokine 
receptor expression. Some chemokine receptors, like CCR4 and CXCR3, are 
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selectively upregulated on KD Treg cells, but not on KD effector T cells. Chemokines 
and chemokine receptors play crucial roles in cell trafficking, lymph cell homing and 
even in autoimmune diseases. They also play essential roles in the pathogenesis of 
type 1 diabetes, considering T cells normally reside in pancreatic lymph node, not 
directly in the pancreatic islets. We propose that the elevated CCR4 and CXCR3 
expression on P2 KD Treg cells facilitates their migration into the pancreas. We have 
preliminary data analyzing the frequency of Treg cells in the pancreas, though further 
repeats are required to consolidate it. Another interesting question is how Ptpn22 
silencing specifically enhances CCR4 and CXCR3 expression on Treg cells. Is it due 
to the enhanced chemokine production by antigen presenting cells or is it a cell 
intrinsic effect? In this project, we examined CCR4, CCR5 and CXCR3 expression, 
as these three have been reported to be involved in the modulation of type 1 diabetes. 
In future work, it may be of interest to comprehensively examine the expression of 
many other chemokine receptors to give an overall picture of how Ptpn22 silencing 
affects chemokine receptor expression. 
 
Besides T cells, Ptpn22 silencing enhanced B cell activation, proliferation and PLC-
γ2 phosphorylation in response to anti-IgM F(ab)’2 or anti-CD40. Strikingly, 
enhanced apoptosis could be found in KD B cells in response to stimulus, which is 
consistent with findings of reduced apoptosis observed in human B cells carrying the 
disease-allele, supporting the idea that Lyp-620W is a gain-of-function variant (Habib 
et al., 2012). B cells play important roles in diabetes. Depletion of B cells either by 
genetic approach or antibody mediated depletion, protects mice from diabetes 
(Serreze et al., 1996. Hu et al., 2007). Although the B cell proportions are normal in 
the lymph nodes and spleens of KD mice, KD B cells may survive less in the pancreas 
where they are stimulated similar to anti-IgM F(ab)’2 or anti-CD40 stimulus. Notably, 
a stronger phenotype can be found in P2 KD compared to P4 KD B cells, as KD 
efficiency is higher in P2 mice. Interestingly, the lack of diabetes resistance in P4 KD 
mice may correlate with a lesser dysfunction of B cells. Further work is required to 
determine the association between B cell apoptosis and diabetes protection, and to 
further clarify the relative contributions of increased number of Treg cells and 
enhanced B cell apoptosis to diabetes resistance.  
 
Unlike the upregulated CD40 expression on dendritic cells (DC) in Lyp-619W 
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knockin mice, the expression of costimulatory and inhibitory signals on antigen 
presenting cells (B cells, DC and macrophages) were not altered in KD mice.  
Similarly, we did not find increased frequencies of germinal centers and the 
dysregulation of follicular T cells, as illustrated by the normal Peanut agglutinin 
(PNA) positive B cells as well as CXCR5 positive T cells. Right now, we cannot 
explain the failure to replicate these phenotypes. The differences between KI and KD 
mice could be accounted for by the different genetic background of the mice used, or 
by the differences in Ptpn22 levels. Interestingly, although the proportions of B cell 
subsets are normal in the bone marrow and the peritoneal cavity, more follicular (FO) 
B cells and less marginal zone (MZ) B cells can be found in the spleens of long-term 
treated P2 mice. Non-circulating MZ B cells are distributed in the marginal zone of 
the spleen, constituting the first line of defense to trap antigens. FO B cells reside in 
follicles of B cell zone in the white pulp of the spleen, are involved in T-B cell 
interaction and  in memory B cell generation. So far, we do not know if the imbalance 
between MZ and FO splenic B cells is related to disease protection. Further work is 
required to clarify this issue. 
 
So far, whether Lyp R620W is a gain- or loss-of-function mutation is still 
controversial. To resolve this issue, we applied inducible RNAi to study the role of 
Ptpn22 in type 1 diabetes and in colitis that are reversely modulated by Ptpn22. The 
rational was that if Lyp-620W is a gain-of-function variant, Ptpn22 silencing should 
prevent or delay diabetes and exacerbate colitis; if the opposite is true, Ptpn22 
silencing should accelerate diabetes and reduce the severity of colitis. We found 
reduced diabetes incidence in the P2 KD mice, but this protection could not be seen in 
the P4 KD mice. This discrepancy could be due to the higher KD efficiency observed 
in the P2 mice, resulting in subsequently enhanced B cell apoptosis and more 
chemokine receptors on Treg cells in the P2 KD mice. Our observation that Ptpn22 
silencing does not increase diabetes risk in either transgenic line strongly supports the 
notion that Lyp-620W is a gain-of-function variant. Moreover, investigators at 
Cambridge University and at the Benaroya Research Institute in Seattle found that the 
accelerated Lyp protein degradation reported by Siminovitch and colleagues is 
possibly due to the failure of the antibody used in these experiments to recognize the 
Lyp-620W variant. Thus, our data support and further confirm that the disease 
associated variant Lyp-620W is a gain-of-function allele.  
 109 
 
In humans, Lyp-620W is a pathogenic allele in diabetes but a protective variant in 
Crohn’s disease. Since P2 KD mice are protected from diabetes, we further tested the 
effect of Ptpn22 silencing on colitis using an adoptive transfer model. NOD.scid mice 
were injected with purified Dox-treated WT, P2 or P4 CD4+CD45RBhi cells to induce 
colitis. Interestingly, elevated disease severity could be observed only in the recipients 
transferred with P4, but not P2 KD CD4+CD45RBhi cells. These results will need 
further confirmation. Of note, colitis was induced with CD4+CD45RBhi cells alone. 
Further experiments will be required to examine the role of Ptpn22 in colitis under 
more complex conditions. For example, colitis could be induced with CD4+CD45RBhi 
in the presence of Treg cells, or using an alternative model, the Dextran Sodium 
Sulfate (DSS) colitis model. 
 
Although there are some limitations to lentivirus mediated RNAi, such as possible 
off-target effects and insertional effects of the transgene (where for example lentiviral 
integration could disrupt endogenous gene expression), we believe the phenotypes we 
observed in KD mice was specifically due to Ptpn22 silencing.  First, we generated 
two transgenic mouse lines bearing different shRNA sequences to control off-target 
effects. In almost all the cases, we found similar results in P2 and P4 KD mice. Due to 
the higher KD efficiency in the P2 mice, stronger phenotype can be found in P2 KD 
mice, such as the more substantial hyperreactivity of P2 KD B cells in response to 
stimulus. We also believe that Dox itself doesn’t have a big impact on mice, as there 
are no differences between WT and Dox-treated WT mice. Second, our inducible KD 
system provides a good control for the insertional effects. In all cases, no difference 
was observed between untreated P2/P4 and WT mice. Third, our findings in inducible 
KD mice replicate several phenotypes in B6 KO mice, including splenomegaly and 
the increase of Treg cell numbers. KO mice are predisposed to autoimmunity, 
imparted by the expanded effector T cell population and elevated serum antibodies. 
Interestingly, KO mice are healthy and even protected from EAE compared to the WT 
B6 mice (Maine et al., 2012). Similarly, strong Ptpn22 silencing in P2 mice protects 
from autoimmune diabetes. 
 
Treg cells play a pivotal role in immune tolerance. On one hand, loss of Treg cells 
accelerates or exacerbates T1D (Salomon et al., 2000; Mellanby et al., 2007). On the 
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other hand, a boost in Treg cells provides a potential therapy for autoimmune patients.  
In the mouse, several approaches have been reported to increase Treg cells to prevent 
or cure type 1 diabetes, for example a lose dose of IL-2 administration, or 
overexpression of TGF-β under control of the insulin promoter (Peng et al., 2004; 
Grinberg-Bleyer et al., 2010). In humans, since the frequency of Treg cells in 
peripheral blood is quite low (1-5% in CD4+ cells), Treg cells can be isolated, 
expanded ex vivo and then infused back into autoimmune patients, which is time-
consuming and costly. Here, we show that Lyp can be a valuable target for the 
treatment of autoimmunity. Ptpn22 inhibition in adult NOD mice specifically 
increases Treg cell numbers, without altering naïve and effector T cell cells. Our 
findings that once Treg cell number is increased, Ptpn22 inhibition is not required to 
maintain this increase at least for 2 months make it more appealing. Meanwhile, more 
GITR is expressed on Treg cells to maintain its suppressive function. This specific 
effect on Treg cells suggests that Ptpn22 inhibition (using a small molecule inhibitor) 
could be a valuable approach to increase Treg cells with limited adverse effects. Since 
several inhibitors against Lyp have been developed, it will be worth testing the 
disease protective effect of these inhibitors in vivo.  Alternatively, these inhibitors 
may be used in the Treg cell expansion ex vivo, considering Ptpn22 inhibition 
enhances homeostatic TCR signaling which can facilitate Treg cell expansion. 
 
In sum, we generated two inducible KD mouse lines: P2 and P4. The inducible KD 
NOD mice replicated many of the phenotypes described for KO and knockin mice, 
including splenomegaly, hyperreactivity of B cells and increased Treg cell numbers. 
Of note, our findings of diabetes resistance in P2 KD mice, hyperreactivity and 
enhanced apoptosis of B cells are in agreement with the proposal that Lyp-620W is a 
gain-of-function variant. Thus, Lyp could be a valuable target for the treatment of 
autoimmune diseases.   
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